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Heparan Sulfate (HS) is a heterogeneous carbohydrate molecule primarily attached to 
proteins on the exterior of mammalian cells. HS interacts with proteins and other 
molecules to affect many important biological processes. The specific HS saccharide 
sequences involved in protein interactions are of interest but have not been extensively 
characterized. This dissertation describes the production of tools and methods to 
study HS interactions of specific saccharide sequences. We have developed a diverse library 
of specific HS structures for which HS interactions can be characterized in a high throughput 
format utilizing a microarray technique. This technology is expected to expedite to 
the identification of therapeutically beneficial HS structures while using small amounts of 
material.  In addition to determining which structures bind to proteins, we have also 
developed methods to determine how tightly they bind and what effects result from in-situ 
modification.  These advances have been pivotal to advancing the understanding of 
biological structure/function relationships and can be utilized by researchers in industry and 
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CHAPTER 1 - INTRODUCTION 
Proteoglycans and Heparan Sulfate 
Glycans are carbohydrate molecules that are highly diverse and play a significant role 
in biology.  Classes of glycans are defined by the monosaccharide content and the glycosidic 
linkage between them.  A wide variety of carbohydrate molecules can be attached 
to proteins and lipids that are involved in recognition, adhesion and signaling [1].  One type 
of glycan is a class called glycosaminoglycans (GAGs).  This class of molecules contains 
amino groups in their structure in the form of glucosamine (GlcN) or other amino containing 
sugars.  There are specific structural differences between these GAG groups of which they 
can be subdivided into groups such as hyaluronic acid (HA), chondroitin sulfate (CS), 
dermatan sulfate (DS), heparan sulfate (HS) and keratan sulfate (KS) (Table 1). 
HS is a heterogeneous glycan expressed on the exterior of all mammalian cells and in 
the extracellular matrix (ECM) [2].  HS is primarily attached to proteins, known as 
proteoglycans, but can be cleaved or shed and be present as free glycan.  These 
macromolecular structures are synthesized in the Golgi apparatus and transported to the cell 
surface, where they are primarily located.  Specific proteoglycans which contain HS are 
aggrecan, glypicans, perlecans, serglycin and syndecans [3].  The differences between these 
groups primarily can be distinguished by their amino acid sequences of the proteins.  
However, the glycan content and location of these proteoglycans also varies.  For example, 
perlecan is found in the basement membrane and contains HS chains [4].  Syndecan is found 
on the cell surface and carries HS, CS and DS [5].  Lastly, serglycin is located intracellularly 
2 
and contains mainly CS but also some HS [6].  These proteoglycans functions include 
recognition, attachment and signaling. 
 
Table 1. Structural characterization of glycosaminoglycan classes represented as 
symbol nomenclature for glycans (SNFG), chemical structure and abbreviated text. The 
SNFG depictions include the glycosidic linkages between monosaccharides. The chemical 
structure displays the chair conformation of the oligosaccharides and includes R groups: R = 
-H or -SO3H; R1 = -Ac, -SO3H or -H. 
 
 
Heparin is structurally similar to HS but contains increased N-sulfation and increased 
Iduronic Acid (IdoA) content [7].  Heparin is known to be attached to serglycin in increased 
amounts on the outside of mast cells [8].  This polysaccharide is used clinically as an 
anticoagulant for treatment and prevention of blood clotting disorders such as deep vein 
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thrombosis, pulmonary embolism, atrial fibrillation, dialysis, surgery and more.  The 
manufacturing of this molecule consists of the isolation and purification of the heparin from 
porcine intestines.  More will be discussed about the clinical use of heparin in a later section. 
Structure of HS 
HS is a specific type of glycan and can be identified by it’s chemical structure (Figure 
1).  It contains repeating disaccharide units consisting of glucosamine-uronic acid linked 
together by 1-4 glycosidic linkages.  The heterogeneous nature of HS occurs as a result of the 
modification of the repeating units as well as the number of repeating units contained in a 
polysaccharide.  The length of these polysaccharides varies widely and is typically 50 to 250 
disaccharide units [9].  Furthermore, each saccharide unit can be modified by biosynthetic 
enzymes such as sulfotransferases or an epimerase.  Sulfotransferase enzymes transfer sulfo 
(-SO3H) groups to specific locations on the glycan.  Specifically, the glucosamine unit can be 
O-sulfated at the 6-O and 3-O positions.  The N-position of glucosamine has been isolated 
from natural sources as unmodified, N-sulfated (GlcNS) or N-acetylated (GlcNAc).  
Additionally, the other portion of the disaccharide unit - the uronic acid portion - can be 
either a glucuronic acid (GlcA) or epimerized to an IdoA (Figure 1).  Both GlcA and IdoA 
can be sulfated at the 2-O-position.  However, IdoA is more likely to contain this 
modification.   These complex structures are involved in many biological processes including 
coagulation, inflammation, neurogenesis, infection and cancer [10].  Moreover, it is known in 






Figure 1. Structure of heparan sulfate. HS is a specific type of GAG and exists on the 
exterior of cells as proteoglycan on the cell surface or in the extracellular matrix. (a) 
Glucuronic acid is glycosidically linked via a 1-4 β-linkage to glucosamine or (b) iduronic 
acid is 1-4 α-linked to glucosamine.  R = -H or -SO3H; R1 = -Ac, -SO3H or -H. 
 
Theoretically, there are 48 possible HS disaccharide structures.  The number of 
possible configurations increases exponentially as you increase the length of the 
oligosaccharide.  For example, increasing from a disaccharide to an octasaccharide (8-mer) 
increases the theoretical possibilities to greater than 5.3 million possibilities (Figure 2).  To 
put this into context, the typical length of HS structures is 50-250 disaccharide units.  At the 
low end, there are theoretically >1084 possibilities of a HS structure containing 50 
disaccharide units, which is greater than the estimated number of atoms in the universe.  
Currently, there is no known template or cellular machinery to guide the HS modifications.  
Therefore, these modifications are often incomplete and result in a highly heterogenous 
mixture that can be difficult to study.  Isolating a significant amount of pure material after 
identification of a specific sequence that affects a biological process is unlikely to yield a 
suitable amount.  Due to enzyme substrate specificity and efficiency, not all possible 
structures are found (in significant quantities) in nature.  By utilizing the biosynthetic 
enzymes for synthesis, naturally occurring structures can be synthesized efficiently.  If 
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enzymes are highly efficient at catalyzing a reaction, it is expected that the produced 
oligosaccharides are more likely to be present abundantly from natural sources. 
 
 
Figure 2. Structure of heparan sulfate with exponential possibilities of theoretical 
disaccharides.  Each HS disaccharide unit can theoretically be 1 of 48 possible structures.  
The uronic acid can be 1 of 4 theoretical configurations and the glucosamine can be 12 
different configurations.  The number of theoretical configurations is defined by the equation 
TP = 48n, where n is the number of disaccharide units. 
 
Biosynthesis – Location, enzymes & diversity 
The biosynthesis of HS is initiated in the Golgi apparatus of a cell.  The Golgi is the 
distribution center of the cell.  It packages proteins to be sent to their cellular destination.  
During this process, proteins are decorated with glycans for expression on the cellular 
surface.  This process involves 3 steps: initiation, polymerization and modification. 
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Step 1: Initiation.  The initial step in O-linked GAG biosynthesis is the attachment of 
a tetrasaccharide linker to a core protein.  This tetrasaccharide linker is highly conserved in 
all GAG containing proteoglycans.  The oligosaccharide is built in a stepwise fashion, 
beginning at the reducing end, proximal to the protein core.  It consists of GlcA on the non-
reducing end followed by two galactose (Gal) and attached proximally by xylose to a serine 
(Ser) in a highly conserved sequence of amino acids: Ser-[Gly/Ala]-Xxx-Gly (Figure 3) [11].  
Each saccharide unit is transferred individually by a glycosyltransferase via a UDP-sugar 
donor.    In the first step, xylosyltransferase attaches a xylose (Xyl) via UDP-xylose to the 
core protein [12].  Two Gal monomers are then transferred by β1,4-galactosyltransferase-I 
and β1,3-galactosyltransferase-II, respectively [13], [14].  GlcA is added as the final piece of 
the tetrasaccharide linker by β1,3-glycuronyltransferase-I [15].  Of note, several other O-
linked glycans can be built off of this tetrasaccharide linker, including CS and HA.  



































Figure 3. Tetrasaccharide linker for glycosaminoglycans. A tetrasaccharide linker 
composed of GlcA-Gal-Gal-Xyl is attached to a serine residue on a core protein. The linker is 
built sequentially by glycosyltransferases which transfer monosaccharide sugar units from a 
UDP-sugar donor.  The tetrasaccharide linker is conserved for all glycosaminoglycans. 
 
Step 2: Polymerization.  After the tetrasaccharide is completed, polymerization of the 
heparan sulfate backbone can be initiated.  The chain length of the HS polysaccharide is 
critical to its function.  Single disaccharides are not typically known to produce biological 
effects.  The length of HS is extended in the Golgi-apparatus in a stepwise fashion by 
alternatively adding GlcNAc and GlcA.  Each monosaccharide is transferred by a family of 
glycosyltransferases known as extosins.  Known members of this family include EXTL1, 
EXTL2, EXTL3, EXT1 and EXT2 [16], [17].  The attachment of GlcNAc by EXTL2 or 
EXTL3 initiates the synthesis of HS and differentiates from the synthesis of CS.  Following 
the addition of GlcNAc, EXT1 and EXT2 are responsible for extending the oligosaccharide 
chain by alternatively adding GlcA and GlcNAc.  The synthesized oligosaccharide consisting 
of -GlcA-GlcNAc- repeating units with no epimerase or sulfotransferase modifications is 
referred to as the backbone structure.  The final length  of HS varies widely but is typically 
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50-250 disaccharide units in length (20-100 kDa) [18].  Importantly, this length is much 
longer than the isolated heparin fragments used for anticoagulation.  HS undergoes cleavage 
by heparinase yielding shorter heparin fragments, typically 12-14 kDa. 
Step 3: Modification.  As mentioned previously, the HS backbone can be deacetylated 
or modified by sulfation at the N-, 6-O, 3-O of GlcN and the GlcA can be epimerized and/or 
2-O-sulfated.  These modifications are achieved by HS sulfotransferase enzymes and a C-5-
epimerase.  Each sulfotransferase can have multiple isoforms which leads to distinctive 
substrate specificities in most cases (Table 2).  The sulfotransferase enzymes transfer a sulfo 
group to the HS backbone from a sulfo-donor, typically 3’-phosphoadenosine 5’-
phosphosulfate (PAPS).  This process is not template driven and therefore, the long chain 
length and multiple HS chains per proteoglycan results in incomplete modification.  As a 
result, HS is a highly heterogenous mixture and characterization or purification of specific 
HS sequences is low-yielding and tedious.  Therefore, the Liu Lab has developed a 
chemoenzymatic method to synthesize specific HS structures which contain a defined chain 
length and a defined sulfation pattern [19].  
 
Table 2. Classification and isoforms of human heparan sulfate biosynthetic enzymes. 










Heparan Sulfate N-Deacetylase/N-Sulfotransferase (NDST)  
 
Heparan Sulfate N-Deacetylase/N-Sulfotransferases (NDST) are a family of 
multifunctional enzymes that acts on the N-position of HS glucosamine residues.  The 
backbone of HS is synthesized in the Golgi apparatus containing GlcNAc.  The NDST 
enzyme has two domains, one is capable of removing the acetyl group and the other acts by 
substituting the N-position of GlcN with a sulfo group donated by cofactor PAPS (Figure 4).  
It is possible for GlcN to remain unsubstituted (GlcNH2).  However, disaccharide analysis of 
isolated HS polysaccharide shows a low frequency of GlcNH2 disaccharides  (< 3%) [20].  
The human NDST family of enzymes consists of four isoforms, NDST1, NDST2, NDST3 
and NDST4 [21], [22].  Each of these enzymes have different substrate specificities and 
tissue distribution.  This adds to the structural heterogeneity of HS and may be important for 
specific tissue function.  In the polysaccharide form of HS, there are domains known as NS-
domains, namely the N-sulfated glucosamine cluster [23].  These domains are correlated with 
increased biological activity and are known to be more highly sulfated.  In order for further 
modifications, i.e. O-sulfation, N-sulfation must first be present [24].  Alternatively, NA-
domains, or N-acetylated glucosamine cluster, are known to be less active in protein binding 























(GlcNAc) (GlcN) (GlcNS)  
Figure 4. Scheme of heparan sulfate NDST enzyme.  Four isoforms of NDST have been 
discovered in the human genome. The NDST enzyme has two domains and is bifunctional.  
The deacetylase domain removes the acetyl group of N-acetylglucosamine. After 
deacetylation, co-factor PAPS transfers a sulfo group to glucosamine (GlcN) using the N-
sulfotransferase (NST) domain. 
 
Heparan sulfate 6-O-sulfotransferase 
 
 There are three known human 6-O-sulfotransferases: 6OST1, 6OST2 and 6OST3.  
These enzymes specifically sulfate the 6-O-position of HS glucosamine (Figure 5).  Each 
enzyme has a different tissue distribution [25]–[28]. 6OST1 has a broad substrate specificity, 
meaning that it is able to add 6-O-sulfation to a wide variety of HS substrates.  So far, there 
is no clear difference in the substrate specificities among different isoforms of 6OSTs. 
Recent studies in our lab have engineered a 6OST enzyme that is able to selectively sulfate 
the non-reducing end glucosamine without further modification [29].  This enzyme 
engineering approach has led to an increase in the number and type of HS oligosaccharides 
which can be efficiently produced using the chemoenzymatic synthesis method.  Previously, 
chemoenzymatic synthesis with wild type 6-OST was able to add 6-O-sulfo groups in an 
uncontrolled fashion.  6-O-sulfating an oligosaccharide with multiple sites available for 6-O-
sulfation would result in low yield of a mixture of products or a high yield of fully 6-O-
sulfated product.  With this new triple mutant engineered enzyme, 6-O-sulfo groups can be 
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added to selected sites as we build from the reducing end and increase the library of HS with 
sufficient yields.   
 6-O-sulfation is known to be important for binding to several proteins.  For example, 
Fibroblast growth factor 1  (FGF1) and Fibroblast growth factor 4 (FGF4) require 6-O-
sulfated HS oligosaccharides [30].  In contrast, Fibroblast growth factor 2 (FGF2) can bind to 
6-O-sulfated HS oligosaccharides, but it is not required[31].  In addition, for binding to 
Antithrombin (AT), 6-O-sulfation at the non-reducing end of the pentasaccharide sequence is 
known to be required [32].  The other two GlcN units that are towards the reducing end of 
the AT binding pentasaccharide can be 6-O-sulfated, but it is not required for binding.  It is 

















(GlcNS) (GlcNS6S)  
Figure 5. Scheme of heparan sulfate 6OST enzymes. 3 isoforms of 6OST have been 
discovered in the human genome.  The 6OST enzyme transfers a sulfo group from co-factor 
PAPS to N-sulfo-glucosamine.   
 
Heparan sulfate 3-O-Sulfotransferase 
 
 3-O-sulfation is a relatively rare but important modification of HS [33].  It has been 
determined that only about 0.5% of HS is 3-O-sulfated [34].  3OSTs have seven isoforms 
(Table 2), the highest number of HS sulfotransferase isoforms, which have a variety of tissue 
distributions (Table 3) [35].  For example, 3OST1 is found at high levels in the 
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cardiovascular and central nervous systems while 3OST5 is found in high levels in skeletal 
muscle.  These enzymes are responsible for transferring a sulfo group from PAPS to the 3-O-
















R = -H or -SO3H
(GlcNS±6S) (GlcNS3S±6S)  
Figure 6. Scheme of heparan sulfate 3OST. Seven isoforms of 3OST have been discovered 
in the human genome.  The 3OST enzyme transfers a sulfo group from co-factor PAPS to N-
sulfo-glucosamine (GlcNS±6S).  The substrate specificity differs between isoforms.   
 
While the specific function and substrate specificity of each 3OST isoform is an 
active area of research, two isoforms have been well characterized for their resulting 
biological function.  3OST1 recognizes a 6-O-sulfated GlcNS that is proximal on the 
nonreducing end to a GlcA [36].  This sequence is the central portion of a known 
pentasaccharide sequence that binds to antithrombin and is responsible for the anti-coagulant 
activity of heparin.  Therefore, studies have shown that isolated heparin that has low 
anticoagulant activity (HSinact) can increase its binding to AT after modification by 3OST1 
and PAPS [37].  Additionally, 3OST3A and 3OST3B have been shown to be important for 
the viral entry of herpes simplex virus (HSV-I).  3OST3 prefers to modify non-6-O-sulfated 
GlcNS that is flanked by IdoA2S on the reducing and non-reducing end.  The removal of HS 
by heparinase or addition of exogenous 3OST3 modified HS was shown to inhibit the viral 
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entry of HSV1 [38], [39].  The modification of the 3-O-position of GlcN can induce 
important biological function of HS.  Research is being conducted to further understand the 
roles that these enzymes play in biology and my research has created a tool to expedite the 
understanding of these enzymes (Chapter 4).  
 
Table 3. HS 3OST isoforms and distribution.  
HS 3OST Isoform Tissue/Organ Distribution 
1 Cardiovascular, Nervous, Pulmonary, Renal 
2 Nervous 
3A Cardiovascular, Placental, Pulmonary, Hepatic, Renal 
3B Cardiovascular, Nervous, Pulmonary, Hepatic, Renal 
4 Nervous 
5 Nervous, Skeletal Muscle 
6 Hepatic, Renal 













Glucuronic Acid Iduronic Acid
(GlcA) (IdoA)  
Figure 7. Scheme of C5-epimerase activity on GlcA. GlcA is epimerized by inverting the 
C5 position to become IdoA through a carbanion intermediate. 
 
Heparan Sulfate C5-Epimerase 
 The GlcA units of HS are also able to be modified by HS biosynthetic enzymes.  One 
modification of backbone GlcA is the epimerization of the C-5 position which converts GlcA 
to IdoA (Figure 7).  This epimerization results in the glycosidic linkage changing from β1-4 
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to α1-4.  The enzyme responsible for the catalytic modification is C-5-epimerase (Epi).  This 
70 kDa protein is the only HS epimerase identified in the human genome.  Its importance for 
survival was determined by being neonatal lethal in c5epi-/- knockout mice.  The 
epimerization is reversible but has been shown to be stable after 2-O-sulfation or with the 
presence of GlcNAc three residues away on the non-reducing end [40]. The epimerization to 
IdoA is a critical component of the pentasaccharide sequence required for binding to 





Figure 8. Scheme of 2-O-sulfotransferase activity on GlcA and IdoA. 2-O-
sulfotransferase (2-OST) transfers a sulfo group to the 2-O-position of either (a) glucuronic 





HS 2-O-sulfotransferase (2OST) transfers a sulfo group to the 2-O position of uronic 
acid (Figure 8).  Only one isoform of HS2OST is found in the human genome and knockout 
of this gene results in neonatal death [41].  There is a known preference for sulfating IdoA, 
but GlcA is also able to be modified by this enzyme.  Epi and 2OST have been shown to co-
localize, which may explain this preference [42].  The enzyme also has a substrate specificity 
for non-6-O-sulfated GlcNS on both the non-reducing and reducing side of the uronic acid 
[43].  This specificity supports the hypothesis that there is a specific order in which the 
modifications are made to produce the antithrombin pentasaccharide from the GlcNAc-GlcA 
backbone.  This order has been proposed to be NDSTC5Epi2-OST6OST 3OST1 










































































































































































Figure 9. Formation of antithrombin-binding HS pentasaccharide. First, the heparan 
sulfate backbone consisting of GlcA-GlcNAc is elongated to an appropriate length.  Then 
NDST is able to deacetylate and transfer a sulfo group to the N-position of glucosamine with 
co-factor PAPS.  Then C5-Epimerase converts glucuronic acid to iduronic acid and 2OST 
transfers a sulfo-group to the 2-O-position of iduronic acid.  6OST is then able to add sulfo 
groups from PAPS to the 6-O-position.  Finally, 3OST adds a sulfo group to the 3-O-position 
of glucosamine.  This specific order of enzymatic is regulated by substrate specificity.  The 
resulting oligosaccharide contains the pentasaccharide sequence required for binding to 
antithrombin.  The results of the enzymatic modifications are highlighted in red. 
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Biological Interactions of HS with Proteins 
 The interactions between HS and biologically relevant molecules such as proteins 
have been historically difficult to characterize and has only been done in a limited number of 
cases.  However, from these studies, it is clear that there is a dependence on specific sulfation 
patterns as well as the length of the HS motif.  Previously, the primary approach has been to 
isolate heterogenous fractions of polysaccharides that have activity and characterize the 
fractions using a variety of approaches.  Chemical synthesis can produce specific saccharide 
sequences, but the tedious nature of protecting and deprotecting to introduce sulfo groups at 
specific locations results in a very low yielding process.  With the efficient method of 
synthesis utilizing chemoenzymatic synthesis, we are now in a favorable position to rapidly 
expand the characterization of HS interactions.  In this section, a brief overview of protein 
interactions with HS and their role in biology will be discussed.  
Antithrombin 
The anticoagulation process in the human body is a highly regulated process that 
requires the balance of many different factors and has been well described in the literature 
[44].  The balance is important because an imbalance can result in serious complications.  An 
increase in coagulation can result in blood clots that could restrict blood flow to critical 
organs such as the brain or lungs.  A clinical example of this is pulmonary embolism in 
which a clot blocks blood flow to the lungs and results in difficulty breathing.  This is 
typically treated with heparin in clinic and patients are sent home with an oral anticoagulant 
from a class of medication commonly known as Novel Oral Anticoagulants (NOAC) [45].  In 
contrast to this, a decrease in coagulation results in an increased risk of bleeding.  Patients 
treated with the vitamin K antagonist, warfarin, must be actively monitored for increased 
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bleeding events.  A common side effect of warfarin treatment that is dosed too high is 
bruising or gastrointestinal bleeding [46].  The body is constantly balancing these conflicting 
imbalances to ensure proper blood flow and enable appropriate delivery of nutrients to vital 
organs. 
 
Figure 10. Coagulation cascade. The two pathways that form a clot are a well-regulated series 
of proteases.  Each coagulation factor, referred to here by their roman numeral, exists in an 
inactive state.  However, if trauma occurs or a damaged endothelial surface is detected, active 
protease can be formed by proteolytic cleavage.  This well-regulated process allows for blood to 
flow freely unless damage is detected which results in activation of the cascade and can form a 
clot.  The two pathways are known as the intrinsic or extrinsic pathways, and they meet at factor 
Xa.  The remaining merged pathway is known as the common pathway.  Antithrombin (AT) is an 
external regulator of this process.  When heparin binds to AT the inactivation of factor Xa and IIa 
results in decreased clot formation.  A specific pentasaccharide sequence of heparin is known to 
catalyze antithrombin activity.  The pentasaccharide is pictured here as the SNFG form. 
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Antithrombin is the protein with the most well characterized HS-protein interaction.  
It is the molecular target for the activity of the FDA approved and commonly used 
anticoagulant, heparin.  To fully understand its activity, you must first understand the 
coagulation cascade (Figure 10).  Humans have two pathways that result in clot formation.  
They are referred to as the intrinsic (contact) and extrinsic (tissue factor) pathway.  The 
intrinsic pathway is the result of a damaged endothelial surface and activates a cascade of 
proteases that activate the next step in the cascade.  This allows for positive and negative 
feedback which results in a well-balanced process.  The damaged surface activates the 
precursor enzyme, Factor XII to become Factor XIIa, which activates Factor XI to activate 
Factor IX.  Factor IXa in combination with Factor VIIIa activate Factor X to Factor Xa, 
which is where the intrinsic and extrinsic pathways meet.  The extrinsic pathway is the result 
of exposed tissue factor as a result of a trauma.  Tissue factor, in combination with Factor 
VIIa cleave Factor X to produce Factor Xa. 
 After the two pathways meet, the rest of the cascade is referred to as the common 
pathway.  Factor Xa and Factor Va form a complex that cleaves Factor II, also known as 
prothrombin, to produce thrombin (Factor IIa).  Thrombin then cleaves Fibrinogen (Factor I) 
to produce Fibrin (Factor Ia) which is the primary building block of a clot.  Factor XIII is 
activated by thrombin to produce the cross-linked fibrin clot.   
This complex process is required for efficient balance of homeostasis.  A protein that 
is an external regulator of the process is called antithrombin.  As the name suggests, it is an 
inactivator of thrombin (Factor IIa) but it also is able to inactivate Factor Xa.  However, the 
activity of antithrombin is weak without heparin.  When antithrombin binds to heparin, it 
increases the affinity for thrombin and Factor Xa.  This complex prevents the progression of 
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the coagulation cascade and results in decreased coagulation [47].  Exogenous heparin has 
been used as an anticoagulant for over 100 years.  In the 1980’s a pentasaccharide sequence 
was determined that is responsible for the anticoagulant activity of heparin [32].  The 
determined sequence was GlcNS6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S.  The central 3-O-
sulfation is a rare, but pivotal element of the binding sequence required for binding to 
antithrombin.  Liu et al. determined a key sulfotransferase as 3OST1 to improve binding of 
HS [48].  In addition to this, it was determined that shortening the length to a tetramer by 
removing the reducing end or non-reducing end glucosamine resulted in a significant 
decrease in binding [32].  Therefore, it was clear that there was a length and sulfation pattern 
dependence on binding to proteins. 
Platelet Factor 4 
Due to the anticoagulant activity of heparin, hospitalized patients are commonly 
treated with heparin to prevent formation of blood clots of which immobilized patients are at 
increased risk.  Heparin has been determined to be safe and effective by the FDA [49].  
However, it has an unwanted side effect that is specific to heparin treatment.  About 1-5% of 
patients treated with heparin experience a decrease in platelets and experience a 
prothrombotic state after heparin therapy [50].  This phenomenon is known as heparin 
induced thrombocytopenia or HIT.  It has been determined that when treated with heparin, a 
complex is formed between heparin and cationic protein, platelet factor 4 (PF4).  The 
complex is recognized by IgG antibodies and forms an immune complex.  This trimeric 
complex binds to Fc receptors on platelets, resulting in activation and aggregation of platelets 
(Figure 11).  Studies have found that the interaction between PF4 and heparin are not 
dependent on a specific sequence of sulfation, but are primarily dependent on the 
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electrostatic charge between HS and PF4[51], [52].  The activation of platelets results in a 




Figure 11. The activity of PF4 and heparin to produce heparin induced 
thrombocytopenia (HIT).  Positively charged PF4 binds to negatively charged heparin 
which is recognized by an IgG antibody.  The trimeric immunocomplex binds to an Fc 
Receptor on the exterior of platelets resulting in platelet activation.  Activated platelets 
release more PF4, which can lead to increased platelet activation and potentially thrombosis.  
 
Interleukin-12 
 The interaction between heparan sulfate and cytokines results in a variety of 
biological responses.  Recently, the interaction between defined HS oligosaccharides and the 
cytokine interleukin-12 (IL-12) was investigated [53].  The activity of IL-12 has been shown 
22 
to be enhanced by the interaction with heparin [54].  IL-12 is released from macrophages and 
signals T-cells to differentiate into T-Helper-1 cells.  This response alerts macrophages in a 
positive feedback loop to initiate the immune response.  The interaction between heparin and 
IL-12 has been determined to be electrostatic and not necessarily based on a specific 
sulfation pattern of HS.  In this investigation, a HS microarray experiment with IL-12 found 
that longer, more highly sulfated HS compounds interacted with the cytokine.  This 
microarray finding is consistent with the proposed mechanism of binding being electrostatic. 
 After binding to the microarray, a series of experiments were conducted to see the 
biological effects of specific oligosaccharides on the activity of IL-12.  It was determined 
that oligosaccharides shorter than an 8-mer did not have an effect.  In addition, compounds 
with three sulfates per disaccharide unit resulted in increased activity over compounds with 
only one or two sulfates per disaccharide.  This finding is similar to that of PF4, but different 
from AT.  In the case of PF4, the interaction is electrostatic and not dependent on a specific 
sulfation sequence.  Antithrombin however, depends on a specific sulfation pattern for 
binding.  Both of these types of interactions can be probed by utilizing microarray 
technology. 
Fibroblast Growth Factor 2 
Many members of the fibroblast growth factor (FGF) family are known to bind to HS 
and are able to be purified by their affinity for heparin.  FGF1 is known as acidic growth 
factor or aFGF.  The co-crystal structure of FGF1 has been solved with a HS mimetic and 
shows that IdoA2S and GlcNS6S are important for binding [30].  FGF2 is known as basic 
fibroblast growth factor (bFGF) and has a very high affinity for HS (KD = ~1 nM) [7].  The 
co-crystal of FGF2 and heparin mimetic shows that a disaccharide of IdoA2S-GlcNS is most 
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significant for binding to FGF2 [31].  HS is known to dimerize FGF2 and there is much 
debate about HS’s role in dimerization of the FGF receptor complex that is required for 
signaling.   
There are two proposed models for FGF dimerization and binding with the FGFR.  
The first model also known as the symmetric model was proposed in 2000 by Moosa 
Mohammadi and co-workers [55].  In this model, based on the crystal structure (PDB: 
1FQ9), the FGF-FGFR complex forms a dimer without heparin, but a positively charged 
heparin binding site is observed.  The FGFR form protein-protein interactions consistent with 
their ability to dimerize and promotion of signaling.  Both FGF and FGFR are known to bind 
HS and the dimer of FGF-FGFR forms a “canyon” which two HS can bind.  In this model, it 
is proposed that two separate HS chains bind and promote the stability of the FGF-FGFR 
complex forming a symmetric 2:2:2 complex of FGF:FGFR:HS.  Notably, the orientation of 
the HS chains has the reducing ends of the two HS chains proximally located.  This finding 
suggests that one HS chain is not sufficient for binding both FGF-FGFR complexes and must 
be two separate HS chains. 
The second proposed model was proposed by Blundell and co-workers in 2000 [56].  
Based on a crystal structure (PDB: 1E0O), this model proposed that a single HS chain is able 
to bridge the dimeric FGF-FGFR complex forming an asymmetric 2:2:1 complex.  In this 
model, it is suggested that there are no contacts between the FGF and FGFR of the opposite 
half of the dimer.  Therefore, the HS is vital to the dimerization and the formation of a dimer.  
There have been several studies that provide evidence for both models, and it may depend on 
the type of FGFR, which member of the FGF family is binding as well as the composition of 
HS available [57].  It is clear that the interactions of HS with proteins are important to 
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biology.  However, there are still many questions that need to be answered in order to 
improve our understanding of these interactions and can lead to beneficial therapeutics for 
patients in need. 
Chemoenzymatic Synthesis of HS and Heparin 
 Similar to biosynthesis, the repetitive steps of chemoenzymatic synthesis consist of 
elongation steps followed by modification.  This allows for specific saccharide sequences to 
be synthesized with defined length and sulfation pattern.  The synthetic route of each 
oligosaccharide begins with a paranitrophenol-glucuronic acid (GlcA-pNP) monomer (Figure 
12).  The paranitrophenol (pNP) functional group allows for the monitoring and purification 
of reactions due to the specific absorbance of pNP at 310 nm.  In order to elongate the 
molecule, either uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) or uridine 
diphosphate N-trifluoroacetyl glucosamine (UDP-GlcNTFA) is mixed with GlcA-pNP.  The 
reaction is catalyzed by the addition of an N-acetylglucosaminyl transferase enzyme from E. 
coli K5 strain, KfiA [58].  The choice of UDP-GlcNAc or UDP-GlcNTFA is dependent on 
the desired final structure.  The GlcNAc in biological heparan sulfate is converted into 
GlcNS via the bifunctional enzyme N-deacetylase-N-sulfotransferase (NDST).  However, 
due to lessons learned in developing the synthetic route, the NDST bifunctional enzyme is 
difficult to produce and conditions necessary for chemical N-deacetylation are too harsh for 
efficient synthesis.  Therefore, if GlcNS is desired, UDP-GlcNTFA is used [59].  This 
product is stable under neutral and mildly acidic conditions.    However, if the desired 
product contains GlcNAc, then UDP-GlcNAc is used.  Further elongations can proceed 
without significant perturbations to the enzyme specificity because GlcNTFA is a bioisostere 
of GlcNAc [60].   
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 The elongation of GlcA residues is catalyzed by an enzyme produced by Pasteurella 
multocida called heparosan synthase 2 (PmHS2) [61].  The previously produced disaccharide 
can be elongated to a trisaccharide with the structure GlcA-GlcNR-GlcA-pNP, where R is 
either acetyl (Ac) or trifluoroacetic acid (TFA), by mixing in UDP-GlcA and PmHS2.  The 
elongation is continued with repetitive steps until the desired length is achieved.  After the 
desired length of HS is produced, the GlcNTFA can be converted to GlcNS by first 
producing GlcNH2 with mildly basic conditions and then modifying with N-sulfotransferase 
(NST) and sulfo-donor, 3'-phosphoadenosine-5'-phosphosulfate (PAPS) (Figure 12c & 12d).  
The N-sulfotransferase portion of the bifunctional NDST enzyme was produced and is used 
efficiently without deacetylase activity [24].  The resulting compound is of desired length 
and contains a desired N-sulfation pattern. 
 Decorating the rest of the molecule with desired O-sulfations is highly dependent on 
enzyme substrate specificity.  As mentioned previously, there is a proposed order of 
sulfations to produce the anticoagulant pentasaccharide.  In order for compounds to convert 
GlcA to IdoA2S, the immediate flanking glucosamines must be N-sulfated (-GlcNS-GlcA-
GlcNS  -GlcNS-IdoA2S-GlcNS-) and cannot contain 6-O-sulfation [43].  Therefore, it is 
assumed that this is the next step to produce the antithrombin binding pentasaccharide after 
N-sulfation (Figure 9).  2-O-sulfation of IdoA is a two-step process of which first, c5 
epimerase acts on the glucosamine and converts GlcA to IdoA.  After, IdoA is sulfated by 
2OST and the product is stable after being sulfated (Figure 12e).  2OST can sulfate GlcA, to 
produce GlcA2S, but this is less common and research is currently ongoing to determine the 
function of these products.   The GlcA2S modification is found to be more prevalent in the 
adult cerebral cortex [62]. 
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It has been determined that 3OST1 requires 6-O-sulfation, so 6OST is presumed to 
act next in the production of the antithrombin binding pentasaccharide (Figure 9).  If 6OST 
acted before 2OST, the 2OST would be ineffective due to substrate specificity [43].  6OST is 
able to add 6-O-sulfation to a variety of different sites, which makes control of 6-O-sulfation 
difficult.  Therefore, as a general practice for efficient synthesis, 6-O-sulfation can be added 
to the reducing end of the molecule and then elongated, or it can be added after reaching the 
desired length and produce a fully 6-O-sulfated structure.  Lin Yi, et. al. were able to 
engineer a mutated form of 6OST that specifically modifies the non-reducing end 
glucosamine which will enable the expanded library of 6-O-sulfated compounds with varying 
6-O-sulfation patterns [29].  Lastly, the 3-O-sulfation is added to the molecules.  Our lab has 
primarily focused on the 3OST1 and 3OST3 modifications.  3OST1 is able to add sulfation to 
the 3-O-position of 6-O-sulfated oligosaccharides specifically to the GlcNS6S on the non-
reducing end of IdoA (GlcNS6S-IdoA±2S  GlcNS6S3S-IdoA±2S).  3OST3 on the other 
hand has different tissue distribution (Table 3) and different substrate specificity [63].  It has 
been determined that 3OST3 prefers to modify non-6-O-sulfated GlcNS that is flanked by 
IdoA2S on both sides (IdoA2S-GlcNS-IdoA2S  IdoA2S-GlcNS3S-IdoA2S).  This enzyme 
would therefore not produce the specific anticoagulant pentasaccharide and is implicated in 
other biological processes such as herpes simplex viral entry [39]. 
 There are more enzymes that are involved in the biosynthesis of natural heparin and 
heparan sulfate.  However, the enzyme substrate specificity and expression of these enzymes 
is an active area of research.  KfiA, PmHS2, NST, epi, 2OST, 6OST and 3OST1 & 3OST3 
were the enzymes that were used to produce the library of compounds used on the microarray 
in this work.  We hope to expand the library of compounds used in the microarray in the 
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future and will undoubtably learn more about the protein interactions of these specific 
oligosaccharides. 
 
Figure 12. Chemoenzymatic synthesis of 3-O-sulfated 6-mer. (a) Synthesis begins with a 
GlcA-pNP monomer and is elongated to a dimer by KfiA.  (b) The dimer is then elongated to 
a trisaccharide by pmHS2.  This process is repeated until the desired length of compound is 
reached.  (c) The oligosaccharide which contains GlcNTFA can be converted to GlcN with 
mild basic conditions (i.e. LiOH).  The remaining modifications can be produced with PAPS 
and (d) NST, (e) Epi and 2OST, (f) 6OST and (g) 3OST1.  The final produced compound is 
Cmpd 76 and Cmpd 48 is produced after 2OST modification.  
Glycan Microarrays 
 A microarray is an array of chemical entities, usually structurally related, that is used 
to screen macromolecules to identify and analyze interactions.  Microarrays have been 
developed that contain DNA, RNA, peptides, antibodies, glycans and more.  The defining 
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advantage of using a microarray is that you can assay many compounds simultaneously while 
using only small amounts of material. The most common format for microarrays is to print 
functionalized version of the molecule of choice onto a modified glass surface, i.e. amino-
functionalized glycans onto a N-hydroxysuccinimide (NHS) functionalized glass slide.  The 
compounds are spatially printed onto the array and screened with a binding molecule of 
choice.  There are multiple ways for detection of the positive binding interactions (Figure 
13): 
1. Using a fluorescently labeled ligand.   
2. Using a fluorescently labeled primary antibody that can detect the hybridized ligand. 





Figure 13. Fluorescent detection of proteins bound on microarray surface. (1) Direct 
detection by fluorescently labeled protein. (2) Detection of bound protein by fluorescently 
labeled primary antibody. (3) Detection of primary antibody bound to protein by 
fluorescently labeled secondary antibody. 
 
Several glycan arrays have been developed and commercialized.  The National Center for 
Functional Glycomics (NCFG) was funded to develop technology to assess protein-glycan 
interactions.  As part of the initiative, they have developed a large glycan microarray 
consisting of 609 mammalian glycan targets [64].  In addition to the mammalian glycans, 
they have also developed a microbial glycan array that consists of over 300 glycans [65]. The 
microarray service is available for use by investigators for a fee.  The array has been in 
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development for almost 20 years and they continuously update the array with new 
compounds.  They are currently on version 5.2 of the mammalian array.  While this service is 
of great use and has resulted in many publications (ncfg.hms.harvard.edu/publications), the 
NCFG microarray library does not currently contain HS oligosaccharides.   
HS microarrays 
  Over the past 20 years, there has been an increasing interest in understanding HS-
protein interactions in order to develop HS-based, disease-modifying 
therapeutics [66].  Having a high throughput method with sufficient diversity which is able to 
determine the structures that bind and also how strongly they bind will be of great value to 
academia and industry.  The glycan microarray technique allows for high throughput 
screening and has helped to understand the interactions between glycans and their binding 
partners while requiring small amounts of ligand [67].  Since the sulfation pattern of HS can 
affect binding to proteins, HS glycan microarrays have been utilized for the screening of HS 
binding interactions.  Due to the difficulty of chemically synthesizing specific HS structures, 
only limited sets of HS have been studied and are detailed below.  Thus far, HS microarrays 
that include decasaccharide (10-mer) or shorter oligosaccharides have been developed (Table 
4).  However, it is known that longer HS oligosaccharides are required for biological 
activity [68].  These limited arrays suggest that researchers undergo the inefficient process to 
chemically synthesize specific HS structures based on the microarray 
results. [69].  Therefore, it is important to develop a microarray which contains greater 
diversity in order to avoid a lengthy chemical synthesis and quickly identify HS structures 
that are likely to be valuable in probing biological questions.    
31 
The Seeberger group and collaborators were pioneers in the construction and 
utilization of HS microarrays.  In the mid 2000’s, an HS microarray was developed 
containing heterogeneous oligosaccharides produced by acidic depolymerization [70].  
Researchers utilized the 2,5-anhydromannose unit produced by nitric acid depolymerization 
of heparin to attach the fragments to an amine-coated glass slide.  The depolymerized 
fractions were purified by p10 column by length.  Compounds with lengths of octasaccharide 
and decasaccharide were further purified by antithrombin affinity column.  These compounds 
with defined length were collected into 6 groups: 8-mers with no affinity, low affinity and 
high affinity and 10-mers with no affinity, low affinity and high affinity.  These 
heterogeneous oligosaccharides were attached to the array at different concentrations and 
screened with Antithrombin (AT), Fibroblast Growth Factor 1 (FGF1) and Fibroblast Growth 
Factor 2 (FGF2).  The binding with AT showed a trend in fluorescence intensity that was 
consistent with the affinity for the AT-column: high affinity fractions > low affinity >> no 
affinity.  Since the mixtures placed on the array were purified using an AT-affinity column, 
this array was able to maintain the specificity of HS interactions using a microarray 
approach.  In contrast, the fluorescence signal with FGF1 and FGF2 showed that all fractions 
displayed binding with the FGFs.  Due to the heterogeneous nature of HS, it is difficult to 
expand the utility of this approach to proteins that have different binding preferences than 
AT. 
In addition to the heterogeneous array, the Seeberger group produced an array that 
contained three chemically synthesized oligosaccharides and several monosaccharides [71].  
The HS structures consisted of GlcNS6S-IdoA2S dimer, tetramer and hexamer.  These 
compounds were synthesized with an amino-tag on the reducing end.  These compounds 
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were spatially arrayed in a microarray format and screened against FGF1 and FGF2.  The 
proteins that bound to the array were detected by fluorescent secondary anti-FGF antibodies.  
It was determined that the tetrasaccharide and hexasaccharide displayed the highest intensity 
and results were similar for FGF1 and FGF2.  This was a pioneering study that showed the 
capability of producing HS microarrays for the determination of specific HS sequences to 
proteins.  Although there were only three HS compounds in this study and only two proteins 
were tested, the potential for determining vast amounts of information utilizing microarray 
technology was demonstrated. 
To build off of the demonstrated success of the previous report, the Seeberger group 
published the results from an expanded array of chemically synthesized heparan sulfate 
oligosaccharides[72].  The library contained twelve specific HS saccharides from monomer 
to hexamer and one heterogeneous mixture of 5 kDa amino-tagged heparin.  The compounds 
were synthesized with a linker containing a terminal primary amine on the reducing end to 
attach the compounds to an NHS-activated glass slide.  FGF-1, FGF-2 and FGF-4 were 
screened against the array and specific sulfation patterns were determined to be important for 
binding.  The results were visualized by detection of a fluorescently labeled secondary 
antibody.  In addition to determining which saccharide sequences bound to the growth 
factors, they also printed the compounds on the array at different concentrations to determine 
binding affinity.  Although they report relative binding affinities between compounds based 
on the maximum fluorescence observed, they do not report dissociation constants for the 
binding affinity studies.  This article primarily focused on the chemical synthesis of the HS 
compounds for the array, but the authors suggest that a major limitation of this approach is 
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the ability to produce a large enough library for a wide application of the microarray 
technology. 
Despite the limited library, the Seeberger array from above which consisted of three 
chemically synthesized monosaccharides, one disaccharide, two tetrasaccharides and six 
hexasaccharides with different sulfation patterns was subsequently used in a variety of 
studies.  In one study, they screened this array against several chemokines: CCL21, IL-8, 
CXCL12, CXCL13, CCL19, CCL25, CCL28 and CXCL16 [73].  They found that each 
chemokine resulted in significant differences of binding with the oligosaccharides on the 
array.  They used primary antibodies to detect the proteins bound on the array and 
fluorescently labeled secondary antibodies for detection and imaging.  They confirmed their 
microarray hits with SPR measurements and results were consistent with microarray results.  
From the results of the array, the hexamer with GlcNS6S-IdoA2S repeating units was 
selected for in vitro chemotaxis experiments.  The hexasaccharide alone was unable to 
mediate chemotaxis, but when a polyamidoamine (PAMAM) dendrimer was coated with the 
hexasaccharide, inhibition of chemotaxis was observed for CCL21, but not CXCL12 or 
CCL19.  These results were similar to the microarray results because CCL21 showed high 
fluorescence signal for this hexasaccharide, but CXCL12 only showed weak signal and 
CCL19 showed no signal.  This study showed the value of utilizing specific saccharide 
sequences to determine biologically active compounds.  In addition, it was determined that a 
positive hit is not necessarily sufficient to affect chemotaxis and perhaps multivalent binding 
is important for biological activity. 
The twelve compound Seeberger HS microarray described above was utilized in two 
more studies that have relevant findings to the development of our HS array.  The array 
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library was screened against NKp30, NKp44 and NKp46D2 [74] .  It was determined that 
compounds that displayed high fluorescence on the array were able inhibit the binding of 
Natural Cytotoxicity Receptors to tumor cells and compounds that did not show activity in 
the microarray format did not inhibit binding.  Although the studies produced positive results 
for the synthetic oligosaccharides, the effect was only modest compared to full length 
heparan sulfate.  This suggests that longer oligosaccharides may be needed for identification 
of biologically relevant microarray results.  Another study aimed to characterize the specific 
HS binding motif required for binding to Annexin A1 [75].  They found that none of their 
chemically synthesized compounds bound strongly to the protein, but heterogeneous 5kDa 
heparin polysaccharide displayed high signal.  They determined that the high negative charge 
was important for interactions, but the spacing of the negative charge was also important.  
This spacing requirement is also argued by Kreuger et al. in 2006 [76].  The Annexin A1 
study shows the importance of having increased diversity on the array, specifically having a 
library with compounds that are longer than a hexamer to determine biologically relevant HS 
binding motifs. 
Shipp and Hsieh-Wilson developed a heterogeneous HS microarray containing 
polysaccharides that were modified by chemical desulfation [77].  The removal of sulfations 
at specific positions can allow for the determination of which sulfations are important for 
protein-glycan interactions.  This extensive study investigated the interactions with FGF1, 
FGF2, FGF4, FGF16 and FGF17.  They were able to find that each member of the FGF 
family had distinct preferences for binding and were consistent with previous reports.  In 
addition to the FGF family, they used the microarray to screen axon guidance proteins: slit2, 
netrin1, sema5b, ephrinA1 and ephrinA5.  They utilized the microarray results to assess axon 
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guidance.  Their results were consistent with the microarray results which showed that 
polysaccharides with high signal on the microarray had expected effects on axon guidance.  
Lastly, they expanded their HS array to include other glycosaminoglycans, including CS, KS 
and HA.  Highly sulfated chondroitin sulfate E and HS showed several interactions with 
proteins studied.  Whereas less sulfated GAGs - KS and HA - had little interaction with the 
proteins in this study.  Although this study gave us some insight into the structural 
characteristics of HS interactions, the major limitation of this study was that the array relied 
upon heterogeneous mixtures of compounds and specific saccharide sequences could not be 
determined. 
The most significant advantage of using a microarray technique instead of other 
techniques is the small amount of material required for studies.  In order to ensure sufficient 
signal could be produced, the Linhardt group developed a heparin microarray with a signal 
amplification technique [78].  A heterogenous mixture of amino-heparin was covalently 
bound to multiple binding sites via sulfo-EGS on poly-L-lysine printed glass slide.  This 
method created a three-dimensional binding site and allowed for more heparin to be bound to 
a single site on the microarray slide.  Compared to previous methods this technique resulted 
in a 4800x amplification in signal.  They used FITC-labeled antithrombin as the reporter for 
this proof of concept study, however the authors suggest that this method could be used for 
further characterization of other heparin binding proteins. 
To expand the utility of HS microarrays, Sugahara and coworkers developed a 
glycosaminoglycan microarray for the identification of anti-GAG antibody specificity [79].  
The array library was produced by covalent attachment of heterogeneous GAGs released 
from proteoglycans.  GAGs attached to the array consisted of chondroitin sulfate, heparan 
36 
sulfate and hyaluronic acid.  The microarray was incubated with monoclonal antibodies 
specific for certain types of glycans and showed high specificity for antibody-glycan 
recognition with no cross reactivity.  To further their results, they also tested growth factors: 
midkine, pleiotrophin, FGF-1, FGF-2, VEGF and HGF.  Because of the heterogenous nature 
of the polysaccharides on their array, they were able to distinguish differences between GAG 
types, but several of the growth factors bound with similar binding profiles.  This result again 
showed the importance of having specific saccharide sequences for the determination of 
specific compounds with potential biological activity.  As a final experiment for the utility of 
this array, they determine the binding specificity for a new antibody, WF6, which reacts with 
chondroitin sulfate C and chondroitin sulfate D.  They confirmed the specificity of this WF6 
and express the potential utility for an array containing naturally occurring GAG’s. 
More recently, the Boons group produced a 47 compound HS microarray [69].  The 
array library consisted of specific, chemically synthesized tetramers.  Using this array, they 
screened the binding of FGF2, CCL2, CCL5, CCL7, CCL13, CXCL8 and CXCL10.  The 
detection of the array was accomplished using a fluorescently labeled secondary antibody.  
They determined that different proteins have different binding preferences for HS structure.  
All proteins recognized multiple HS structures on the array.  However, it was determined that 
different proteins had different modes of recognition.  For example, some proteins such as 
CCL7, exhibit a preference for higher sulfated compounds rather than a specific type of 
modification.  On the other hand, CCL10 displays a clear preference for compounds that 
contain specific saccharide sequences and is not dependent on the number of sulfations per 
tetrasaccharide.  Specifically, a GlcA in the third position is not tolerated and only 
compounds that contain IdoA±2S show significant signal.  This study shows the value in 
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developing a heparan sulfate microarray with specific saccharide sequences.  However, it is 
noted in their conclusion that there are limitations in using such short HS sequences.  
A 2019 study by Sharp et al. developed a method to purify fractions of heterogeneous 
enoxaparin with high enough purity to distinguish results on a microarray [80].  The method 
utilizes 3 types of purification and prints the collected fractions in a microarray format.  In 
this study, they screen their array library with FGF2.  Interestingly, they identify fractions 
that bind with higher fluorescence intensity than the heterogeneous LMWH starting material.  
Although this method shows promise in isolating specific compounds contained in the FDA 
approved enoxaparin, further analysis of the fractions is needed to characterize the hits.  In 
contrast, chemoenzymatic synthesis can efficiently produce specific oligosaccharides that are 
characterized before printing on the array.  
In 2015, the Liu lab began the combination of chemoenzymatic synthesis with the 
microarray technique [81].  In this study a library of nine HS oligosaccharides was 
synthesized by subjecting chemically synthesized HS structures to 6-OST and 2-OST 
enzymatic modification.  The library consisted of 9 specific compounds: a disaccharide, a 
tetrasaccharide and 7 hexasaccharides.  After synthesis, the library was adhered to an NHS-
glass slide and screened with FGF2 and detected by FITC-labeled anti-FGF antibody.  Only 
two specific compounds containing full N-sulfation, 6-sulfation and IdoA2S bound, although 
their length differed – tetrasaccharide and hexasaccharide.  The array was able to show 
selectivity for specific saccharide sequences and showed the value of utilizing 
chemoenzymatic synthesis for the production of large libraries of compounds in order to 
assess binding to proteins.   
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In 2017, the Liu lab synthesized a diverse HS microarray in terms of sulfation pattern 
[82].  However, the length of the compounds on the array was limited to heptasaccharides.  
This study was the first time that a library of chemoenzymatically synthesized HS 
oligosaccharides were used in a HS microarray.  Importantly, this array included compounds 
that ranges from non-sulfated to compounds that contain NS, 6S, IdoA2S and 3S.  This array 
was screened with AT and 3OST1 and showed unique binding profiles for each.  
Specifically, the compound that contained the 3-O-sulfated pentasaccharide sequence that is 
known to bind AT showed the highest fluorescence intensity.  This array showed the power 
of combining chemoenzymatic synthesis with the microarray technique.  Although the 
compounds used in the array were heptasaccharides and longer than most previous HS 
arrays, it was clear that the array could be expanded to include a more diverse library of 
compounds to gain more information about HS interactions with proteins. 
HS microarrays that have been developed thus far have both strengths and 
weaknesses.  The primary objective of this dissertation was to utilize chemoenzymatically 
synthesized HS structures to develop and utilize a diverse HS microarray.  The array 
developed in chapter 2 contains defined structures with varying length and sulfation patterns, 
including 3-O-sulfated HS compounds.  Additionally, the oligosaccharides will be printed at 
different printing concentrations to assess the effects of printing density and we will use the 
method of direct protein labeling for detection (Figure 13-1).  This strategy will combine the 
strengths of the previously developed HS microarrays and is expected to improve our 
understanding of HS structure/function relationships.  Compounds found to be positive hits 
in the microarray format can easily be used in other assays and production can be increased 
in most cases for large scale production to advance the field of glycobiology. 
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Table 4. Summary of Heparan Sulfate Microarray Studies. 
Year Group # of compounds 
Compound 
Length Proteins Screened: 
2006 Seeberger 3 2-6 FGF1, FGF2 
2006 Seeberger 12 1-6 FGF1, FGF2 & FGF4 
2006 Seeberger 6 8 &10 AT, FGF1 & FGF2 
2007 Shipp 5 
Poly FGF1, FGF2, FGF4, FGF16, FGF 17, 
slit1, netrin1, sema5b, ephrinA1, 
ephrinA5 
2007 Seeberger 12 1-6 CCL32, IL-8, CXCL12, CXCL13, CCL19, CCL25, CCL28 & CXCL16 
2008 Linhardt 1 Poly AT 
2009 Seeberger 12 1-6 NKp30, NKp44, NKp46D2 
2011 Seeberger 12 1-6 AnnexinA1 
2013 Sugahara 9 Poly Antibody, midkine, pleiotrophin, FGF1, FGF2, VEGF & HGF 
2015 Liu 9 2-6 FGF2 
2017 Liu 13 7 AT, 3OST1 
2017 Boons 47 4 FGF2, CCL2, CCL5, CCL7, CCL13, CXCL8, CXCL10 





CHAPTER 2: DEVELOPMENT OF HS MICROARRAY 
Introduction 
 Microarray technology has been utilized in a variety of different contexts.  Small 
amounts of material are able to be spatially arrayed onto a solid surface which allows for a 
rapid and efficient analysis of large libraries of compounds.  Typically, compounds that are 
structurally similar are screened together in order to gain insights into the specificity of the 
ligand of choice.  For example, large libraries of nucleic acids, peptides and glycans have 
been utilized in a microarray format.  Glycan microarrays have been developed in a variety 
of different contexts, which has resulted in an improved understanding of the overall function 
and specificity of the human glycome [83].  However, having an effective method to produce 
a large library of structurally diverse and defined compounds is pivotal to producing a useful 
glycan microarray. 
 As described in detail in the introduction, there have been multiple attempts to 
develop HS microarrays.  However, major limitations in these studies include the 
inefficiency of chemical synthesis of HS oligosaccharides with lengths longer than 
hexasaccharide or due to the structural heterogeneity of isolated HS fragments [84].  
Fortunately, a highly efficient chemoenzymatic method for synthesizing HS oligosaccharides 
with a defined length and sulfation pattern has been developed [19].  Therefore, we have 
decided to combine the efficiency of chemoenzymatic synthesis with the rapid 
characterization of microarray technology to produce the most diverse HS microarray 
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developed to date.  This approach will allow for the identification of specific saccharide 
sequences with defined characteristics that can be immediately used in biological assays. 
 Previous HS microarray libraries have consisted of heterogenous mixtures or 
oligosaccharides with defined structure which are shorter than heptasaccharide (7-mer).  
These studies are described in detail in Chapter 1 and summarized in Table 4.  Although 
shorter oligosaccharides may be able to provide information about specific binding motifs, 
longer HS oligosaccharide chains have been shown to be required for the biological activity 
of HS [68].  Therefore, we have developed an array library which contains compounds from 
tetrasaccharide (4-mer) to octadecasaccharide (18-mer).  With increased diversity of 
compound length, compounds which display activity in the microarray format and are 
expected to affect biological activity can be immediately studied.  In contrast, previous arrays 
with shorter oligosaccharides can suggest which structural motifs might be important for 
including in a final structure, but further synthetic efforts would need to be done in order to 
produce a biologically relevant compound. 
In addition to the length of oligosaccharide being important for protein recognition, 
the specific sulfation pattern is also important.  HS can be modified to contain sulfations at 
specific positions by sulfotransferases.  Specifically, the 2-O, 3-O, 6-O and N- positions of 
HS can be sulfated.  This modification increases the negative charge of the molecule and 
alters the ability of HS to interact with biological targets.  Notably, the addition of sulfation 
at specific positions can either inhibit or enhance the interaction with proteins.  A well-
studied example is HS’s interaction with antithrombin (AT), a protease inhibitor protein 
involved in the coagulation cascade (Figure 10).  It has been determined that there is a 
critical 3-O-sulfation at the central glucosamine unit of a pentasaccharide that is required for 
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binding to AT [32].  The specific structure has been defined as GlcNS6S-GlcA-GlcNS6S3S-
IdoA2S-GlcNS6S.  This pentasaccharide is highly modified, containing all types of sulfation, 
but the interaction with AT is diminished without the 3-O-sulfation at the central GlcN 
residue.  Notably, HS can also be modified by a C-5-Epimerase which converts glucuronic 
acid (GlcA) to iduronic acid (IdoA).  The IdoA unit is more likely to be 2-O-sulfated than 
GlcA.  In contrast to the 3-O-sulfation, the 2-O-sulfation of IdoA is not required for AT 
binding and activity [85].  Studying the structure activity relationships (SAR) resulting from 
specific modification of HS that can drastically alter the interaction with protein ligands is 
something that can be assisted by the utilization of a microarray technique.  
In order for the HS oligosaccharides to be printed on the array, they must first be 
modified with an appropriate linker to be covalently attached to the chip.  The 
chemoenzymatic synthesis method developed in our lab utilizes a para-nitrophenol (pNP) tag 
which has a specific ultraviolet (UV) absorbance at 310 nm.  This tag can be converted into 
an aniline by reduction and can then be further modified with additional types of tags.  For 
this study, most compounds are converted from an oligo which contain an N-(6-
azidohexanamidyl) p-aminophenyl tag.  The azido group can similarly be reduced to contain 
a N-(6-aminohexanamidyl) p-aminophenyl tag (Figure 14).  The amino group is highly 
reactive with N-hydroxysuccinimide (NHS) coated glass slides, which are commercially 
available and commonly used in microarray studies [67].  The efficient conversion from 
azido-tagged oligosaccharides to amino-tagged oligosaccharides allowed for us to develop a 
large library of compounds that can be efficiently arrayed in a microarray format.  
A major concern regarding the production of microarrays is the ability to have 
consistent amounts of material delivered per spot on the microarray.  The ability to deliver 
43 
highly accurate volumes of material has been systematized by the production of sophisticated 
instrumentation.  In this study, we utilize a robotic arrayer that is able to deliver picoliters of 
aqueous solution utilizing piezoelectric dispensing [86].  Before solutions were introduced to 
the arrayer, compound concentrations were determined based on their amino content by a 
fluorescence assay.  This technique allowed for a consistent delivery of oligosaccharides with 
known concentrations.  In this study, we printed each oligosaccharide at three different 
concentrations: 50, 25 and 12.5 µM.  This is a feature of our microarray that allows us to gain 
increased information about how the compound is interacting with the protein. 
HS microarrays are a valuable tool for improving the understanding of HS-protein 
interactions.  However, production of large libraries of HS oligosaccharides with defined 
length and sulfation patterns has previously been limited by the efficiency of synthesis.  With 
the development of a highly efficient chemoenzymatic synthesis method to produce HS 
oligosaccharides, we can now produce large libraries of HS compounds that can be used in a 
microarray format.  In this chapter, we will discuss the methods and results utilized in the 
development of a highly diverse and defined HS library.  We will also describe the array 
layout, the compounds contained within the library and the process of printing compounds 
onto the array.  In the following chapters, we will describe results that have been determined 
by utilizing the HS microarray and novel microarray techniques that have been used to 
further characterize HS interactions. 
  
44 
Materials and Methods 
Heparan Sulfate Compounds:  
The chemoenzymatically synthesized compounds [19] used to prepare the compounds 
on the array are commercially available via Glycan Therapeutics 
(www.GlycanTherapeutics.com).  N-(6-azidohexanamidyl) p-aminophenyl-tagged (azide-
tagged) oligosaccharides were reduced with palladium on carbon (Pd/C) catalyzed 
hydrogenation to produce the amino modified glycans.  200 µg of each azide-modified 
oligosaccharide was dissolved in water in a flask to make a 1 mg/mL 
solution.  Approximately 0.25 mg of Pd/C was added to the solution and the reaction vessel 
was vacuumed and refilled with H2 three times.  The mixture was stirred under hydrogen 
balloon pressure for 4 hours.  The reduction was monitored by electrospray ionization-mass 
spectrometry (ESI-MS) (Figure 14, Appendix I).  If the reaction was incomplete at 4 hours, 
as determined by ESI-MS, it was allowed to continue to stir under hydrogen balloon pressure 
until completion.   
The final solution was filtered with a 0.2 mm syringe filter to remove the Pd/C.  The 
syringe and filter were washed with deionized water several times.  The filtrate was 
lyophilized using a centrivap overnight.  The resulting powder was diluted with 1 mL of 50 






Figure 14. Example ESI-MS of Cmpd 93-N3 and Cmpd 93-NH2. (a) ESI-MS spectrum for 
Cmpd 93-N3 (molecular weight = 2093.76). (b) chemical structure of Cmpd 93-N3. (c) ESI-
MS spectrum for Cmpd 93-NH2 (molecular weight = 2067.76). (d) chemical structure of 
Cmpd 93-NH2. 
 
Determination of concentration:  
A fluorescent ninhydrin assay was utilized to determine the concentration of amino 
modified sugar in each stock solution (Figure 15).  Stock solution (2.5-20 μL) of amino-
tagged HS was diluted to 100 μL with 50 mM phosphate buffer (pH = 8.5).  In a 96 well 
plate, the sample was mixed with 75 μL of ninhydrin (Sigma-Aldrich) dissolved in 75% 
dimethyl sulfoxide/25% phosphate buffer (50 mM, pH=8.5) and 75 μL of 10 % 
phenylacetaldehyde dissolved in ethanol.  The mixture was shaken at 60°C for 30 min in a 
microplate shaker.  The microplate was allowed to cool to room temperature and 
fluorescence intensity was measured (excitation 390 nm, emission 490 nm) using a 
microplate fluorescence scanner.  In the plate, 0-70 µM of β-alanine dissolved in 100 µL of 
50 mM phosphate buffer (pH = 8.5) was used to develop a standard curve.  The resulting 





Figure 15. Chemical scheme of ninhydrin assay.  Ninhydrin and phenylacetaldehyde are 
mixed with a solution containing the amino-tagged heparan sulfate to produce a fluorescent 
product.  The amount of fluorescence is determined by a plate reader with excitation at 390 
nm and absorbance at 490 nm. 
 
Figure 16. Sample β-alanine standard curve determined from fluorescent ninhydrin 
assay.  100 µL samples of β-alanine ranging from 0-70 µM were mixed with ninhydrin and 
phenylacetaldehyde in a 96-well plate.  The resulting fluorescence intensities were measured 
at 490 nm absorbance.  The results were measured in triplicate and are plotted as mean FU ± 
SD.  The best fit line, equation and R2 are displayed on the chart. 
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Microarray printing: Printing and adherence of compounds to array 
Amino-tagged HS oligosaccharides were spatially arrayed by an S11 robotic arrayer 
(Scienion) onto a dry NHS-functionalized glass slide (Nexterion Slide H).  Each compound 
was printed with 36 spots in a 6 x 6 square (Figure 18).  Each square contains 3 sets of 12 
spots, with each set consisting of a different printing density: 12.5 μM, 25 μM and 50 μM 




Figure 17. Preparation of HS Microarray using NHS modified Nexterion Slide H.  An 
amino-tagged oligosaccharide was spatially arrayed using a S11 robotic arrayer (Scienion).  




After printing, slides were incubated overnight at RT in a saturated (NH4)2SO4 
humidity chamber (relative humidity = 81%) to allow the reaction to reach maximum 
attachment.  Unreacted oligosaccharides were removed by washing with water and unreacted 
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succimidyl groups were blocked in a solution of 50 mM ethanolamine (Aldrich).  A solution 
of 50 mM ethanolamine in PBS with 0.01 % Tween (pH = 8.5) was prepared.  50 mL of the 
ethanolamine solution was placed in a 50 mL conical tube and the 25 mm x 75 mm x 1 mm 
glass slide was inserted into the tube.  The tube was placed in a 50°C water bath for 1 hour.  




Figure 18. Layout of HS Microarray.  Left: Location of compounds on array by Cmpd #; H 
= unfractionated heparin.  Middle: Appearance of HS microarray after printing.  Each 
compound is printed in a 6x6 square in sets of 12 that differ by printing concentration (right). 
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Results 
Modification of oligosaccharides for adherence to array 
Preparing the HS compounds for the microarray was accomplished by modifying 
chemoenzymatically synthesized compounds with an N-(6-aminohexanamidyl) p-
aminophenyl linker for attachment to an NHS modified glass slide (Figure 17).  94 
chemoenzymatically synthesized oligosaccharides with an N-(6-azidoohexanamidyl) p-
aminophenyl were modified in one step to a primary amine via hydrogenation.  The 
reduction step is high yielding and was typically complete in 4 hours.   
Ninhydrin Assay - Determination of stock solution concentration  
Due to the small amount, an accurate final concentration of stock solution was 
difficult to determine by standard methods.  The amount of oligosaccharide was determined 
based on the primary amino group on the linker after reduction.  We utilized a fluorescent 
ninhydrin assay to determine the concentration of our final reduced compounds (Samejima et 
al. 1971).   This method required small amounts of material and also corrected for any 
incomplete reduction.  Typically, UV absorbance at 245 nm can estimate the concentration of 
N-(6-aminohexanamidyl) p-aminophenyl or N-(6-azidohexanamidyl) p-aminophenyl tagged 
oligosaccharides.  However, an incomplete reduction would result in an 
inaccurate calculation due to the amino-tag and azide-tag having similar UV 
absorbances.  Previous studies showed that azide-tagged compounds do not bind significantly 
to the NHS-modified glass slide and therefore a small impurity would not affect the 
microarray [82].  Concentrations were determined in triplicate and the ninhydrin assay results 
were consistent and comparable to expected yields.  A summary of the final concentrations 
determined by the ninhydrin assay is included in Appendix II.   
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Library of HS compounds 
The 94 specific compounds on the array could be subdivided into the following 6 groups 
based on sulfation pattern (Figure 2, Supplementary Table SI): 
1. Six non-sulfated (N-acetylated) glycans ranging in length from pentasaccharide to 
dodecasaccharide (Cmpds 1-6).  
2. Eighteen oligosaccharides without O-sulfation, which contain varying levels of N-
sulfation ranging from tetrasaccharide to dodecasaccharide (Cmpds 7-24).  
3. Twenty-three compounds all of which contain varying levels of 6-O-sulfation (Cmpds 
25-47).  
o Of note, these compounds also contain varying levels of N-sulfation, however 
they do not contain IdoA(±2S) or 3-O-sulfation.  
4. Twenty-eight IdoA2S containing oligosaccharides ranging from hexasaccharide to 
18-mer (Cmpds 28-75).   
o These compounds are also N-sulfated and 6-O-sulfated to varying extents, but 
all compounds in this group contain at least one IdoA2S.  
5. Six 3-O-sulfated compounds ranging in length from hexasaccharide to 
dodecasaccharide (Cmpds 76 -81).  
o This group of compounds is highly sulfated due to enzyme substrate 
specificity and all compounds contain varying levels of N-sulfation, full 6-O-
sulfation, at least one IdoA2S and at least one 3-O-sulfation.   
6. Thirteen IdoA containing oligosaccharides ranging in length from hexasaccharide to 
nonasaccharide (Cmpds 82-94).   
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o These compounds specifically contain an IdoA that is not 2-O-sulfated and 
contain varying levels of N-sulfation(±6-O-sulfation).  
The 95th compound in the array library is unmodified heparin (H).  All 
oligosaccharides were attached covalently on the surface of the array chip via the reducing 
end as depicted in Fig 1.  Although H is not specifically affixed on the NHS-coated glass 
slide, we are able to see several proteins recognize and show significant binding signal to the 
immobilized H spots; however, in some cases the protein binding to heparin on the chip is 
different from that observed in solutions.   
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Figure 19. Microarray library.  Compound numbering (Cmpd #) and symbol nomenclature 
for glycans (SNFG) structures on the microarray.  Compounds 1-94 are modified at the 
reducing end to contain an amine-linker for adherence to the microarray chip. H is 
unfractionated heparin and is not modified. 
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Array Printing 
 The array was spatially arrayed in a predetermined format by a robotic arrayer.  
Approximately 400 picoliters of HS solution was delivered to the NHS-coated glass slide.  
Twenty slides were printed in the same run.  The array robot prints twelve spots per slide for 
a total of 240 spots per compound (20 slides x 12 spots) at each concentration.  Therefore, 
each slide contains 3,420 spots.  The spots are spaced approximately 400 µm apart and the 
spot diameter is approximately 70 µm. 
 
Discussion 
 The chemoenzymatic method to synthesize specific HS oligosaccharides was a major 
advancement towards the understanding of HS structure and function relationships.  
However, since HS is able to be modified in a variety of different ways, it is important to 
have a method for quickly understanding which modifications are relevant to HS-ligand 
interactions.  The microarray technique allows for a large library of compounds to be 
assessed simultaneously for their interactions with biological targets.  The interactions can be 
probed with fluorescently labeled proteins, antibodies, viral capsids or even cells [67].  The 
combination of chemoenzymatic synthesis with the microarray technique leads to a rapid and 
efficient screening method that allows for characterization of HS interactions. 
 Since the microarray technique is inherently on a solid surface, there are some 
limitations to this approach.  Limitations include the restricted mobility of the 
oligosaccharides and the high concentration of oligos in one spot that may be different than 
the cellular environment.  However, the small amount of material that is required per 
experiment can outweigh the limitations of the technique.  The robotic arrayer used in this 
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experiment is able to deliver 10-800 picoliters of material per drop [86].  As an example, 
when we deliver 12 spots of 50 µM Cmpd 78 (MW = 2050 Da), less than 1 ng of material is 
spotted.  Previous studies which utilized heparan lyase treatment of HS microarray slides 
determined that only ~10 pg of material is actually adhered to the plate per spot [82].  
Therefore, with small amounts of material we can produce significant results.  In contrast, 
other methods such as ITC require several micrograms of oligosaccharide to determine the 
binding properties of a single compound in solution.  We recognize the inherent limitation of 
an assay on a solid support.  However, the advantage of gaining information on binding 
preferences of many compounds while requiring only picograms of material will be 
advantageous to characterizing HS interactions. In chapter 3, we will explore this further and 
demonstrate that results observed in the microarray format are consistent with previous 
reports of HS interactions. 
 The diverse library of HS compounds produced for this study is unprecedented.  We 
have strategically included compounds with varying lengths, compounds with varying 
sulfation patterns and printed compounds at different printing densities to expand the 
understanding of HS interactions.  The lengths included in the library range from tetramer to 
18-mer.  Importantly, a series of nine 12-mers are included that varies in sulfation pattern 
from non-sulfated (Cmpd 6) to a highly modified compound that contains two 3-O-sulfations 
(Cmpd 81).  3-O-sulfation is a rare modification that is only observed in about 6 percent of 
isolated heparan sulfate [87].  As mentioned previously, the 3-O-sulfation has been 
determined to be critical for the anticoagulant activity of HS.  Despite the known importance 
of this modification, it has not been included in a majority of previously reported HS 
microarrays.  Heterogeneous mixtures of HS printed on microarrays will likely contain small 
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amounts of 3-O-sulfated HS.  However, utilizing the chemoenzymatic method of synthesis to 
produce specific 3-O-sulfated oligosaccharides will improve our ability to parse out the 
importance of this modification. 
 The monitoring and characterization of compounds that were prepared for the array 
was primarily done by mass spectrometry (MS).  The reduction of the azide-tag to an amino-
tag was easily observable by ESI-MS (Figure14).  Since we start with small amounts of 
material (200 µg), assessing the purity by HPLC would result in the addition of significant 
amounts of salt and/or unnecessary loss of material due to further purification.  Importantly, 
previous studies have demonstrated that azido-tagged oligosaccharides do not bind efficiently 
with the NHS-coated surface [82].  We typically characterize the concentration of oligo 
based on the pNP tag that has a distinctive absorbance at 310 nm.  After conversion to the 
azido-tag, the 310 nm absorbance is lost.  The UV absorbance of the azido-tag and amino-tag 
are similar, and therefore it was important to utilize a different method for determining 
concentration.  Therefore, we characterized the concentration of oligosaccharide based on the 
primary amine content via a fluorescent ninhydrin assay.  Utilizing this method, we were able 
to determine the amount of amino-tagged oligosaccharide that was produced and could 
differentiate from any remaining azido-tagged starting material.  The estimated concentration 
determined by the ninhydrin assay were consistent with the expected yields. 
 After stock solutions were prepared in sufficient quantities for printing by the 
microarrayer, 50 µM solutions were prepared in a 96 well plate.  The 50 µM plate was used 
to create two additional 96-well plates containing 25 µM and 12.5 µM solutions.  The 
solutions were then transferred to a 384-well plate to be utilized by the robotic arrayer.  
Twenty microarray chips were produced in a single run.  The layout was designed to group 
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compounds with similar sulfation patterns in similar locations on the chip.  For example, all 
compound that are non-sulfated are in the upper left of the array and all compounds that 
contain a 3-O-sulfation are in the upper right.  Within hours, all 95 compounds were printed 
at three different concentrations on twenty different microarray chips.  After printing, the 
remaining unreacted succimidyl groups were passivated using ethanolamine.  In chapter 3, 
we will discuss the results determined by the utilization of these array chips. 
 In conclusion, we have utilized the efficiency of chemoenzymatic synthesis to 
produce a large library of defined HS compounds for use in a microarray format.  A robotic 
arrayer was utilized to deliver picoliters of material to a modified glass surface in a 
predetermined layout.  With this tool, we can investigate the interaction of specific HS 
oligosaccharides with biological ligands.  The library we produced consists of compounds 
with a variety of lengths and sulfation patterns.  The length of oligosaccharides contained in 
the library ranges from tetramer to 18-mer.  Additionally, the library consists of compounds 
with different sulfation patterns, from non-sulfated compounds to compounds that contain N-
sulfation, 6-O-sulfation, 3-O-sulaftion, IdoA and 2-O-sulfation.  The diversity contained 
within the library will allow for the determination of specific lengths and sulfation patterns 
that contribute to HS binding to biological targets.    
58 
 
CHAPTER 3: UTILIZATION OF THE HEPARAN SULFATE MICROARRAY 
TECHNIQUE TO ASSESS PROTEIN INTERACTIONS 
 
Introduction 
Determining the specific HS sequence required for binding to proteins is an important 
aim in glycobiology.  Combining chemoenzymatic synthesis and microarray techniques 
allows for rapid progression towards this goal.  Herein we have developed a method for 
screening a diverse array of specific HS compounds against several proteins.  In order to 
further these studies, we have also characterized the binding affinity of up to 29 HS 
structures simultaneously and results are consistent with previous literature.  We believe that 
this will be a valuable tool for industry and academic researchers aiming to characterize the 
biological significance of HS binding interactions.  
Utilizing the library of compounds described in Chapter 2 of this dissertation, we first 
aimed to confirm the ability of the microarray technique to distinguish between specific 
compounds.  This was accomplished by hybridizing the array with proteins that recognize 
previously described and well characterized sulfation sequences.  After demonstrating that 
the microarray technique produced results consistent with previous reports, we then showed 
that the microarray can be utilized to determine structure activity relationships (SAR) by 
comparing similar compounds in the library.  Additionally, we have utilized techniques to 
further characterize the interactions utilizing known methods and newly developed methods. 
AT was chosen as the protein to probe the utility of the microarray due to the well 
characterized interaction and critical requirement of 3-O-suflation.  AT was labeled with a 
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fluorescent dye, Alexa Fluor 488 NHS Ester, which selectively labels lysine residues.  Based 
on known requirements of AT binding, the microarray technique used in this study was 
sensitive enough to detect only compounds which contain the required pentasaccharide 
binding sequence (Figure 22).  The positive hits in this study displayed a signal that was 
more than 40 times greater than the background signal.  Compounds without 3-O-sulfation 
that contained the same or greater level of sulfation displayed only background binding.  
Compounds that only differed by a single sulfation, namely the 3-O-sulfation did not show 
significant binding signal.  The microarray library and hybridization technique showed 
excellent selectivity and high signal to noise.  From this study, we determined that a signal 
that is more than ten times the background would be considered a positive hit and have 
defined the “binding threshold” for each experiment based on the background.   
To increase our confidence in this technique, we tested the six positive hits for their 
anticoagulant activity.  Amino-tagged compounds were assayed for their ability to bind AT 
and inhibit anticoagulant Factor Xa.  All compounds that showed activity on the array also 
showed activity in the Anti-Xa assay (Table 5).  This furthered our confidence that we would 
be able to utilize the results determined by the microarray to quickly produce meaningful 
results in follow up experiments without a lengthy synthesis.  The results demonstrated that 
all six compounds, regardless of length, were able to bind AT and inhibit Xa in a similar 
concentration range.   
To extend the utility of the microarray technique and characterization of HS 
interactions, we developed a method for determining the strength of binding to the HS array.  
By utilizing a 16 well microarray chamber, we were able to assess the ability of the 
compounds on the array to bind different concentrations of protein simultaneously.  The 
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results displayed that the six compounds bound AT with surface binding affinities (KD,surf) in 
the 200-350 nM range.  We tested the binding affinity of two compounds by isothermal 
titration calorimetry (ITC) and determined similar sub-micromolar binding affinities.   
After the results of AT were able to show the utility of the microarray technique and 
were consistent with previous results, we characterized the interactions with FGF2, PF4 and 
Il-12.  All proteins tested showed a unique subset of compounds that displayed binding signal 
above the binding threshold.  For FGF2 and PF4, we also assessed the surface binding 
affinity of the positive hits.  The binding affinity results of FGF2 displayed binding affinities 
that were similar to previous reports of FGF2 binding.  However, PF4 displayed peculiar 
results.  For AT and FGF2, we observed results that displayed increasing fluorescence 
intensity with increasing concentration of protein that reached a maximum and stayed 
constant at higher concentrations (Figure 23a and Figure 26).  In contrast, with increasing 
concentrations of PF4 we observed an increase in fluorescence intensity that reach a 
maximum and returned to baseline with increasing concentrations of PF4 (Figure 31).  This 
shows that proteins may behave differently in these assays and more proteins will need to be 
studied in order to fully understand the implications of these findings. 
In this chapter, we validate our 95-compound array by showing that antithrombin 
(AT) binds only to compounds that contain the known 3-O-sulfated pentasaccharide 
sequence (Atha et al. 1985) and display anti-factor Xa activity.  After confirmation, we then 
confirmed the requirement of IdoA2S for the binding of FGF2 (Guimond et al. 1993).  We 
were able to determine binding affinities of AT and FGF2 utilizing a microarray technique, 
and results are similar to previous binding studies. After confirmation of the utility of the 
array, we also screened IL-12 and PF4. A unique binding profile was determined for all 
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proteins studied. Overall, these studies demonstrate the value in combining chemoenzymatic 
synthesis with a microarray technique to advance the understanding of HS-binding 
specificity. 
 
Materials and Methods 
Preparation of fluorescently labeled proteins:  
Fluorescently labeled protein was prepared by direct labeling with Alexa Fluor 488 
NHS Ester (Thermo Scientific, Waltham, MA, USA).  Protein (100 µg) was mixed with 3 
equivalents of unfractionated heparin to prevent labeling of binding site and 100 mM 
NaHCO3.  The mixture was allowed to equilibrate for 15 min at room temperature followed 
by the addition of 3-10 equivalents of Alexa Fluor 488 NHS Ester.  The reaction was left to 
proceed at room temperature for 1 h. The reaction mixture was purified by heparin agarose 
column and PBS buffer exchanged using a centrifugal filter.  Labeled proteins were 
visualized by fluorescence SDS-PAGE by using a Typhoon 9500 (Figure 20).  The excitation 
wavelength was 495 nm, the emission wavelength was 519 nm and a low protein binding 
(LPB) filter was utilized for imaging.  Final concentration and degree of labeling was 




Figure 20. Fluorescence SDS-PAGE gel.  Lane A = Antithrombin (AT), Lane B =  
Fibroblast Growth Factor 2 (FGF2), Lane C = Platelet Factor 4 (PF4), Lane D = Interleukin 
12 (IL-12) and Lane E = PageRuler Plus Prestained Protein Ladder (Thermo Scientific) 
 
Microarray slide hybridization:  
A 10 μg/mL solution of fluorescently labeled protein was prepared by diluting the 
protein in a PBST/Tris/BSA solution (PBS, 0.05% Tween 20, 20 mM Tris, 10% BSA, pH = 
7.5).  100 μL of the mixture was placed between a dry arrayed glass slide (Chapter 2) and a 
cover slip.  The hybridization was carried out for 1 hour in a saturated (NH4)2SO4 humidity 
chamber.  Next, the cover slip was removed and the slide was washed by shaking in 50 mL 
of a PBST solution containing 1% BSA and 20mM Tris in a 50 mL conical tube.  Lastly, the 
slide was rinsed with water and dried by centrifugation.   
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Scanning microarray slides:  
Dry hybridized slides were scanned by a GenePix Pro 4300A scanner (Molecular 
Devices).  Slides were scanned using a 488 nm laser and analyzed by GenePix Pro software.  
The gain was selected based on the number of saturated spots; the maximum gain was used 
that resulted in zero saturated spots.  No spots were removed from analysis and the results are 
reported as the ‘mean 488 fluorescence intensity – background’ as calculated by the software. 
 
 
Figure 21. Schematic representation of the microarray binding affinity assay.  
Compounds are arrayed into wells I-XIV in the same layout for each well and hybridized 




Microarray Binding Affinity (KD,surf):  
Positive hits as determined by the initial 10 µg/mL screen were spatially arrayed in a 
format compatible with a 16 well-FAST slide incubation chamber (GVS Filter Technology).  
50 μM of oligosaccharides (7 compounds for AT and 29 compounds for FGF2) were printed 
in the same layout 14 times per slide.  The unreacted succimidyl groups on the slide were 
blocked with ethanolamine solution. 100 μL of fluorescently labeled protein with different 
concentrations (0-4 μM, Figure 21) was pipetted into individual wells and allowed to 
incubate for 1 hour.  The protein solution was gently washed with water, then shaken in 
PBST containing 1% BSA, then rinsed with water again and dried by centrifugation.  The 
plate was read using a fluorescent scanner as before, and the average fluorescence intensity 
was plotted against the concentration of the fluorescently labeled protein.  The binding 
affinity was determined using GraphPad Prism 8 version 8.2.0.  The resulting curves were 
analyzed as Langmuir isotherms [88] using equation 1:  
𝐹𝐹 = Fmax [𝑃𝑃][𝑃𝑃]+𝐾𝐾D,surf     (1) 
Where F is the fluorescence intensity, Fmax is the maximum fluorescence, [P] is the 
concentration of protein and KD,surf is the binding affinity. 
Anti-Xa activity:  
The Anti-Xa assay is a chromogenic assay based on a previously reported method 
[89].  Human Factor Xa (Enzyme Research Laboratories) was diluted to 2 μg/mL in PBS.  S-
2765 (Chromogenix), a chromogenic substrate, was diluted to 1 mg/ml.  Oligosaccharides 
were diluted to concentrations of 0-10 μM.  An average molecular weight of 16,000 Daltons 
was used for heparin [90].  Also, an Antithrombin solution was prepared consisting of 0.03 
mg/mL AT and 1 mg/mL BSA in PBS.  Oligosaccharide solution (5 μL) was mixed with 60 
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μL of the AT/BSA solution and shaken in a 96 well plate for 2 min.  Then the Factor Xa 
solution (100 μL) was added and shaken for 4 min. Lastly, S-2765 (30 μL) solution was 
added and the absorbance was immediately measured at 405 nm continuously for 2 min.  The 
maximum slope was plotted against the concentration of oligosaccharide to determine the 
IC50 values.  The IC50 values were determined by GraphPad Prism version 8.2.0.    
Isothermal Titration Calorimetry:  
The equilibrium dissociation constant (KD) of Cmpds 77 & 80 versus AT was 
determined by ITC.  The oligosaccharide was dialyzed in 100 mM sodium phosphate buffer.  
The protein was concentrated using the same buffer in a centrifugal filter.  The instrument 
used was a MicroCal Auto-ITC200 and the software was Micro Analyzer ITC 200.  For the 
experiment, 200 μL of 10 μM AT (unlabeled) was added to a sample cell and titrated with 
38.2 μL of oligosaccharide (100 μM) in 2 μL increments over 1 hour (note: first injection is 
0.2 µL).  The titration curve of kcal/mol versus molar ratio (oligo/protein) was obtained by 
measuring the heat generated after injection of 2 μL oligosaccharide, integrating with respect 
to time and normalizing for concentration. The KD values were determined by fitting the 
thermodynamic data for the binding enthalpy (ΔH) during titration.  Results are presented as 
the mean ± standard deviation (n = 2). 
 
Results 
Antithrombin: SAR, Binding Affinity & Anti Xa Activity 
One benefit of having longer oligosaccharides on an array is the ability to determine 
the specific structures that can have a significant biological effect.  Upon screening 10 μg/ml 
of fluorescently labeled AT, only compounds 76-81 exhibited a significant fluorescent signal 
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corresponding to binding.  The specific order of fluorescent intensities at 50 μM printing 
concentration was 78 > 81 = 80 = 77 > 79 > 76 > H (Figure 22).  In addition, there was a 
decrease in fluorescence signal for each compound at decreasing printing densities (50 μM > 
25 μM > 12.5 μM).  Cmpds 76-81 contain 3-O-sulfation; consistent with known structural 




Figure 22. Binding of heparan sulfate oligosaccharides to AT. (a) 10 µg/mL fluorescently 
labeled AT screened against 95 compounds printed at 50 µM (blue), 25 µM (red) and 12.5 
µM (green).  Each compound was printed 12-times at each concentration for a total of 36 
spots per compound.  Results are represented as mean ± SD for each printing density.  The 
inset is compounds that bind AT (Cmpds 76-81) and UFH (H). The binding threshold for this 
experiment was 440 FU and is depicted by a red dashed line.   
 
In order to further characterize the interaction with 3-O-sulfated compounds 76-
81, we determined the binding affinity of six compounds simultaneously using the 
microarray technique (Figure 23a). After the initial screen, new array chips were prepared 
that only contained compounds 76-81 and H.  These compounds were spatially arrayed for 
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use with a 16 well FAST slide incubation chamber (GVS).  14 different concentrations (0 - 
4 µM) of fluorescently labeled AT were incubated in 14 wells, each containing the same 
array of oligosaccharides (Figure 21).  After normalization, the binding affinities of Cmpds 
76-81 ranged from 199.0 nM – 367.9 nM (Table 5).  The order of binding affinity was 
determined to be 78  > 79 > 77 > 76 > 80 > 81. Notably, H did not show a significant 
fluorescent signal in the initial screen nor in the binding affinity studies.  Recall that H is not 
modified with an amino linker and therefore may be positioned differently in relation to the 
glass slide.  This alternate orientation may cause the binding site to be inaccessible. 
We did not observe the binding of H to AT in the microarray format. This is likely 
attributed to the orientation of H on the chip.  In our view, having an in depth understanding 
of how the orientation of H affects the AT binding deviates from the purpose of this project.  
The major utility of the microarray analysis is to narrow down the oligosaccharide hits.  The 
binding properties of the oligosaccharides should not be over interpreted without additional 
biological analysis.  As a research tool, whether H behaves similarly or dissimilarly to their 
oligosaccharide counterparts in the microarray analysis is not the limit for the technology. 
The binding of heparin to a target protein in solution can be carried out separately without 
using microarray analysis. 
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Figure 23. AT binding affinity study results and Fmax vs KD,surf plot (a) Microarray 
binding affinity results for Cmpds 76-81. Results are presented as a normalized fluorescence 
intensity vs concentration of AT.  Compounds were printed 10 times each at 50 µM printing 
concentration and each point is normalized mean fluorescence intensity ± standard deviation. 
(b) Scatter plot of the calculated maximum fluorescence intensity (Fmax) observed in the 
microarray binding studies vs the calculated surface dissociation constant (KD,suf) determined 
in the same experiment for AT (Linear Regression, p = 0.21). Linear regression was 
conducted using GraphPad Prism 8.0. 
 
Table 5. AT microarray binding affinity (KD,surf) and anti-Xa Activity (IC50).  
Cmpd # KD,surf ±  SE (nM)a Coefficient of Determination (R2) 
Anti Xa activity 
(IC50,nM)b 
76 333 ± 12 0.92 13 ± 3 
77 289 ± 22 0.96 10 ± 1 
78 199 ± 15 0.85 8 ± 1 
79 273 ± 33 0.99 16 ± 7 
80 347 ± 33 0.97 32 ± 3 
81 368 ± 31 0.96 21 ± 3 
H n.d. n.d. 2.5 ± 1 
amicroarray binding affinities are represented as KD,surf ± SE 




The binding affinity of Cmpds 77 and 80 against AT was determined by an 
isothermal titration calorimetry (ITC) binding measurement.  The results indicated that the 
binding affinities were 252 ± 11 nM and 807 ± 28 nM, respectively (Figure 24).  Data are 
generally consistent with the results found using the microarray technique.  The HS 
microarray determines the binding affinity of multiple HS structures with accuracy and in 
high throughput. 
 
Figure 24. ITC analysis of 77 and 90 with structures.  (a) ITC analysis of AT binding to 
Cmpd 77 .  (b) ITC analysis of AT binding to Cmpd 80. (c) Chemical structure of Cmpd 77; 
R = p-nitrophenol.  (d) Chemical Structure of Cmpd 80; R = p-nitrophenol. 
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We analyzed the anti-Xa activity of Cmpds 76–81 to demonstrate that these AT-
binding oligosaccharides show anticoagulant activity. The six compounds that showed 
significant signal upon initial screening all showed similar anti-Xa activity ranging from 10.7 
to 44.4 nM (Table 5), consistent with previous reports [63]. In summary, we were able to 
demonstrate the utility of our HS microarray by screening a well-characterized protein, 
determining the binding affinity of positive hits, confirming the binding affinity 




Figure 25. Binding of heparan sulfate oligosaccharides to FGF2. Fluorescently labeled 
FGF2 (10 µg/mL) screened against 95 compounds printed at 50 µM (blue), 25 µM (red) and 
12.5 µM (green).  Each compound was printed 12-times at each concentration for a total of 
36 spots per compound.  Results are represented as mean ± SD for each printing density 
(n=12).  The inset is IdoA2S containing compounds (Cmpds 48-81) and UFH (H). The 
binding threshold for this experiment was 970 FU and is depicted by a red dashed line. 
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Fibroblast Growth Factor 2: SAR and binding affinity determination  
FGF2, a well-characterized heparin-binding protein, was next screened to further 
confirm the utility of our microarray technique.  The results showed that only glycans 
containing IdoA2S (Cmpds 48-81) residues displayed fluorescent signal when screening with 
10 μg/mL FGF2 (Figure 25).  These results are consistent with previous characterizations of 
the binding requirements of FGF2 [91].  In addition, the SAR can be shown using the 
microarray technique.  For example, Cmpd 46 and Cmpd 94, both 9-mers containing four N-
sulfo groups and four 6-O-sulfo groups but do not contain the required IdoA2S, do not show 
significant fluorescence signal.  However, Cmpds 68 and 71, contain one and two IdoA2S 
residues, respectively, and display significant signal indicating a binding event.   
 
In addition to screening FGF2 at a single protein concentration, we also sought to 
determine the binding affinity of the glycans that showed significant signal.  We selected 29 
glycans for analysis and simultaneously screened these against 0-4 μM FGF2.  The measured 
binding affinities varied from 4 nM for Cmpd 75 to 3 μM for Cmpd 65 (Table 6, 
Supplementary Figure S6).  The KD,surf values were comparable to previously reported values 
obtained by a similar technique with chemically synthesized HS oligosaccharides in a 
microtiter plate [92].  Based on these results, it was clear that FGF2 shows a difference in 
affinity depending on the sulfation pattern.  As an example, the 8-mer series shows that the 
relative binding affinity of Cmpds 58 >> 61 > 63 > 79.  This trend is consistent with previous 
literature stating that FGF2 requires GlcNS and IdoA2S for binding and although 6-O- and 3-




Figure 26. Microarray binding affinity results for FGF2. Results are presented as 
fluorescence intensity vs concentration of FGF2.  Compounds were printed 10 times each at 
50 µM printing concentration and each point is mean ± standard deviation. 
 
Table 6. FGF2 microarray binding affinity (KD,surf) and maximum fluorescence (Fmax) 
determinations.  
Compound KD (nM) 
Fmax 
(FU) R




H 102 798 0.79 65 3157 4334 0.53 
50 968 6658 0.91 66 2691 4747 1.00 
52 1605 2719 0.96 67 1434 3273 0.97 
53 377 6286 0.96 68 355 3549 0.89 
54 556 5450 0.97 69 126 5462 0.95 
55 105 1350 0.68 70 94 7217 0.95 
56 97 3423 0.85 71 112 6305 0.90 
57 1345 2738 0.98 72 25 13050 0.95 
58 2996 4601 1.00 73 49 14460 0.94 
59 1614 3287 0.97 74 69 15402 0.96 
60 206 3152 0.79 75 4 8187 0.74 
61 152 5284 0.90 79 23 4336 0.81 
62 103 6820 0.96 80 26 9706 0.85 
63 37 3780 0.80 81 43 24169 0.97 
64 64 4750 0.81     
 
 
Interleukin - 12: Microarray screen and SAR 
After the array was validated with AT and FGF2, it was used to screen other proteins 
with less characterized binding profiles.  IL-12 is a central regulator of human immunity and 
is a heparin-binding protein [94].  A previous collaboration with our lab published data of IL-
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12 with a 52 compound microarray which showed longer, more highly sulfated compounds 
displaying the highest signal [53].  Similar results were determined with the 95-compound 
array (Figure 27 and Figure 29).  Of note, four new compounds were identified that were not 
present on the previous array.  These newly identified compounds 56, 63, 64 and 79 are 
highly sulfated with >2 sulfate groups per disaccharide unit and therefore are consistent with 
the previous results. 
 
 
Figure 27. Binding of heparan sulfate oligosaccharides to IL-12. 10 µg/mL fluorescently 
labeled IL-12 screened against 95 compounds printed at 50 µM (blue), 25 µM (red) and 12.5 
µM (green).  The binding threshold for this experiment was 1190 FU and is depicted by a red 
dashed line. Each compound was printed 12-times at each concentration for a total of 36 
spots per compound.  Results are represented as mean ± SD for each printing density (n=12).  
The insets are compounds 68-81 and H. 
 
Platelet Factor 4: screen, SAR and binding affinity 
PF4 is a cationic protein involved in an adverse effect of heparin therapy known as 
heparin induced thrombocytopenia (HIT) [95].  On screening with 10 μg/mL PF4, an 
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electrostatic interaction was observed.  Compounds with various sulfation patterns were able 
to bind, but longer, more highly charged compounds showed the highest fluorescent signals 
(Figure 28 and Figure 29).  The significance of the combination of 2-O-sulfation with 6-O-
sulfation is displayed by the 12-mer series: Cmpd 24 < 47 = 72 < 74 < 81. Compounds 
containing NS6S or NS2S (Cmpds 47 & 72, respectively) display similar fluorescence 
intensities.  However, with NS6S2S (Cmpd 74), the signal increases approximately 8-fold 
and the signal is further increased upon addition of 3-O-sulfation (Cmpd 81).   
 
 
Figure 28. Binding of heparan sulfate oligosaccharides to PF4. 10 µg/mL fluorescently 
labeled PF4 screened against 95 compounds printed at 50 µM (blue), 25 µM (red) and 12.5 
µM (green). The binding threshold for this experiment was 230 FU and is depicted by a red 
dashed line.  Each compound was printed 12-times at each concentration for a total of 36 
spots per compound.  Results are represented as mean ± SD for each printing density (n=12).  
The insets are compounds 68-81 and H. 
 
Lastly, we attempted to determine the correlation between number sulfation and 
fluorescence intensity for different proteins (Figure 29 and Table 7).  PF4 and IL-12 behave 
similarly in that they have a mediocre R2 values (0.43 and 0.44, respectively) for compounds 
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not containing IdoA2S and 0.68 and 0.87, respectively, for compounds containing IdoA2S.  
Data suggest that there is a correlation between sulfation and binding, while the binding 
correlation appears to be stronger when IdoA2S residues are present in the oligosaccharides. 
FGF2 on the other hand has a low R2 value (0.01) for compounds that do not contain 
IdoA2S, but an R2 value of 0.69 for compounds containing IdoA2S indicating a preference of 
IdoA2S for binding.  The data suggest that the correlation exits when the IdoA2S residue is 
present. AT has a highly specific interaction represented by a low R2 value (0.00-0.16) 
including when controlling for the presence of IdoA2S, suggesting that the sulfation and 





Figure 29. Scatter plots of the 50 µM printing density observed fluorescence intensity 
(FU) vs number of sulfations per compound. (a) 10 µg/ml antithrombin, (b) 10 µg/ml 
fibroblast growth factor 2, (c) 10 µg/ml platelet factor 4 and (d) 10 µg/ml interleukin 12.  
Each plot contains a best-fit line computed by linear regression for compounds 1-47 & 82-94 
which do not contain IdoA2S (blue dotted line) and compounds 48-81 which do contain 
IdoA2S (orange dotted line).  The solid black line is the best fit line for linear regression of 
all compounds (1-94).  The binding threshold is portrayed by a horizontal dashed red line.  







Table 7. Linear regression results for fluorescence intensity vs sulfation level of AT, FGF2, PF4 and IL-12. 
Protein 
Compounds 1-47 & 82-94 (-IdoA2S) Compounds 48-81 (+IdoA2S) All Compounds (±IdoA2S) 
Comments Slope Intercept P-value R2 Slope Intercept P-value R2 Slope Intercept P-value R2 
AT 0.3 14.4 0.45 0.00 401.7 -1428 <0.0001 0.14 295.8 -926.9 <0.0001 0.16 Requires 3-O-Sulfation  
FGF2 16.8 117.4 0.0045 0.01 1590.0 -4886 <0.0001 0.69 1234.0 -3766 <0.0001 0.58 Requires IdoA2S  
PF4 26.3 -55.8 <0.0001 0.43 759.1 -3283 <0.0001 0.68 525.7 -1779 <0.0001 0.55 Electrostatic Interaction, Cmpd 47 > Binding Threshold  





The microarray presented in this paper contains large structural diversity in terms of 
the chain length, sulfation patterns and printing densities.  We have shown that the array is 
sufficiently diverse to demonstrate SAR down to the presence of a single sulfo group 
drastically changing the recognition and binding to a heparin-binding protein.  This level of 
detail should produce valuable information for those interested in substrate recognition and 
other biological questions.  One proposed method of value is the determination of positive 
and negative controls that are very similar in structure, differing in a single sulfo group.  In 
addition, we were able to show increased utility of the microarray technique by determining 
the binding affinity of compounds and have shown that this technique will be valuable in not 
only determining compounds that bind, but also how strongly they bind.  As seen in Tables 5 
& 6, the previously held notion that a higher fluorescent signal at a single concentration is 
indicative of increased binding affinity [72], [80] may not always be true.  Figure 23b and 
Figure 30 plot the calculated maximum fluorescence intensity (Fmax) observed in the 
microarray binding studies vs the calculated surface dissociation constant (KD,surf) and there 
is no observed correlation between these measurements. We also have evidence to suggest 
that all proteins will not behave the same in microarray binding affinity studies which may be 
indicative of protein function (Figure 31).  For example, it is unclear why the binding of PF4 




Figure 30. Scatter plot comparing FGF2 fluorescence vs KD,surf.  The calculated 
maximum fluorescence intensity (Fmax) observed in the microarray binding studies vs the 
calculated surface dissociation constant (KD,suf) determined in the same experiment for FGF2 
(Linear Regression, p = 0.12).  The inset in (b) is zoomed in to the range 0-200 nM.  Linear 
regression was conducted using GraphPad Prism 8.0. 
 
Compounds were printed at different spot densities to add to the diversity and 
complexity of the array.  In most cases, a decrease in fluorescence signal was observed with a 
decrease in printing density.  One of the main advantages of using a microarray approach is 
the relatively small amount of ligand required for screening.  A top printing density of 50 µM 
was selected to provide sufficient signal (> 10x background).  Concentrations above 50 μM 
begin to plateau and do not produce more fluorescence signal [82].  A 4-fold reduction (50 
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μM – 12.5 μM) in printing concentration is sufficient to produce a significant decrease in 
fluorescence signal, therefore demonstrating that a binding event is real. 
AT is one of the most well characterized heparin-binding proteins.  Heparin binds to 
AT, catalyzing the inactivation of Factor Xa.  When Factor Xa is inactivated, the result is a 
decreased production of thrombin and decreased coagulation [96].  The compounds on the 
array that bind to AT (Cmpds 76-81) all contained the required pentasaccharide sequence 
containing a 3-O-sulfated glucosamine residue.  It can clearly be seen that there is no 
correlation between the binding fluorescence intensity and sulfation density (# of sulfo 
groups per saccharide). For example, Cmpd 78 has significant fluorescence signal while its 
sulfation density is only 1.14.  Cmpd 74 has a higher sulfation density of 1.33, but it merely 
has a background fluorescence signal (Table 8). These results show the importance of 
understanding the structural determinants of HS binding because one sulfo group at a specific 











50 µM (FU)a 
Structureb Total Sulfations 
Number of sulfo 
group/saccharide 
53 7.6 ± 6.2 GlcA-GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 7 1.00 
56 10.8 ± 7.7 GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 8 1.14 
74 78.3 ± 20.4 GlcNS6S-GlcA-(GlcNS6S-IdoA2S)4-GlcNS6S-GlcA-R 16 1.33 
78 23837 ± 3052 GlcA-GlcNS6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-R 8 1.14 
aAT Fluorescence Intensities are represented as mean FU ± standard deviation (n=12). 
bR = N-(6-aminohexanamidyl) p-aminophenyl 
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In addition, the binding affinities of AT were determined using a microarray 
technique.  Similar sub-micromolar binding affinities for compounds 76-81 in a range of 199 
to 368 nM were determined (Table 5).  ITC was used to compare the surface AT binding 
affinity determinations for 77 and 80 to a solution phase study.  The KD for 77 and 80 
measured by ITC was 0.3 μM and 0.8 μM, respectively, consistent with the KD,surf 
determination. This technique is beneficial in further characterizing HS binding interactions 
and can be simultaneously determined for multiple oligosaccharides.  
FGF2 is a high affinity heparin-binding protein that has been characterized to bind 
specifically to IdoA2S containing HS and this result was confirmed by our 
microarray.  Although 6-O-sulfation and 3-O-sulfation are not required for binding to FGF2, 
they can enhance the interaction as shown by an increase in fluorescence.  The array contains 
several IdoA compounds that are epimerized, but not 2-O-sulfated (Cmpds 82-94).  
However, even though the analogous IdoA2S compound (i.e., Cmpd 53) shows fluorescent 
signal, the IdoA compound (i.e., Cmpd 87) is unable to bind, once again showing that a 
specific modification on a specific residue can influence the interaction.  The twenty-nine 
IdoA2S containing compounds showed a fluorescence signal above background.  Binding 
affinities (KD,surf) were determined to further characterize the interaction between FGF2 and 
the 29 compounds.  Turnbull et al. isolated a high affinity binding HS oligosaccharide and 
determined that N-sulfate groups and IdoA2S were essential for binding to FGF2 (Turnbull et 
al. 1992).  This finding is consistent with our results as Cmpd 75, an 18-mer with repeating 
IdoA2S-GlcNS, displays the highest binding affinity in our binding affinity studies (4 nM). 
A full listing of FGF2 binding affinity results can be found in Table 6, but here, we 
will discuss a series of 8-mers that show an increasing binding affinity with the addition of 
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sulfo groups at specific positions.  Cmpd 58 contains a single IdoA2S unit and no 6-O-
sulfation.  This compound shows a low binding affinity for FGF2 of about 3 μM. As 
mentioned earlier, a similar 8-mer with an unsulfated IdoA is on the array (89), but does not 
show a fluorescence signal, indicating no significant binding.  With the addition of another 
IdoA2S, Cmpd 61 improved its binding affinity 20-fold without significantly changing the 
maximum fluorescence intensity (Fmax = 4600 FU and 5200 FU, respectively).  Adding 6-O-
sulfation (63) improves the binding affinity about 2-fold and adding 3-O-sulfation (79) 
further improves the binding affinity 2-fold with a final KD,surf determination of 23 nM.  The 
addition of 6-O-sulfation does not always increase the binding affinity.  For example, the 
analogous 12-mers show a lower binding affinity for 6-O-sulfated Cmpd 74 compared to 72 
(69 nM vs 25 nM, respectively). Previous studies on a similar chemoenzymatically 
synthesized heptasaccharide containing the same sulfation pattern as 56 but with a different 
tag, afforded a KD of 200 ± 4 nM using affinity co-electrophoresis [98]. SPR studies show 
the binding affinity of HS to FGF2 is 35 nM [99].  The resulting KD,surf determined by the 
microarray technique was within this range for 14 out of 29 compounds tested, including 56. 
These results demonstrate the reliability and consistency of the microarray binding affinity 
determination.   
Other proteins were screened against the 95-glycan microarray at a single 
concentration (10 µg/mL).  A recent publication screened IL-12 against a 52-glycan 
microarray [53].  The results indicated that longer, more highly sulfated oligosaccharides 
were the best binding partners of IL-12.  The same protein was screened using our 95-glycan 
microarray and resulted in similar binding results.  The 52-glycan microarray previously 
studied contains all of the 12-mers and one 18-mer that are on the 95-glycan microarray, so 
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no improved binding partners were detected.  However, four shorter, highly sulfated glycans 





Figure 31. Plots of fluorescence intensity (FU) vs log [PF4] (nM) for microarray binding 
affinity studies. (a) Results with 0-4 mM PF4.  (b) Results with 0-16 μM PF4.  
 
PF4, a positively charged, tetrameric protein was also screened using the microarray 
technique.  The microarray shows that the binding between HS and PF4 is an electrostatic 
interaction and is dependent on overall charge.  Figure 29 & Table 7 describe the 
fluorescence intensity vs number of sulfations and shows a significant positive correlation for 
all proteins tested (p<0.0001) when including all compounds.  Longer, more highly sulfated 
glycans showed the highest fluorescence activity.  However, when the background threshold 
(10x background) was considered, PF4 is the only protein in this study to bind Cmpd 47, a 
NS6S 12-mer with 12 sulfations.  Alternatively, the 3-O-sulfated AT binding 




hope to find a compound that binds AT and not PF4 to potentially reduce the risk of HIT, but 
this array did not produce such a compound.  Lastly, PF4 shows a distinct profile for the 
microarray binding affinity experiment (Figure 31).  We expected to see a sigmoidal shaped 
curve with the fluorescence intensity reaching a maximum and remaining constant.  
However, what we observe is an increase, followed by a decrease in observed fluorescence 
intensity as concentration increases.  We are not certain if this is due to a decrease in binding 
due to electrostatic repulsion at higher concentrations or perhaps due to a change in 
fluorescence observed [100].  Further studies will need to be done in order to understand this 
serendipitous result. 
In the future, we plan to expand the complexity of the array to include more HS 
diversity in terms of length and sulfation.  In addition, we will expand beyond HS structures 
and include other glycosaminoglycans, specifically chemoenzymatically synthesized 
chondroitin sulfate glycans (Li et al. 2017).  We also plan to expand our capabilities to detect 
binding of complex targets beyond individual proteins and screen bacteria and viruses.  We 
specifically chose to deal with fluorescently labeled proteins in this study.  However, using 
unlabeled proteins with primary or secondary labeled antibodies can be used as an alternate 
method of detection, if necessary [67].  Utilizing these techniques, our microarray can be 
rapidly expanded to include more structures that will detect the specific binding motifs of 
many more GAG binding structures. 
In conclusion, we have developed a high throughput HS microarray that is able to 
screen heparin-binding proteins.  The results determined by the array are consistent with 
previous literature but we were also able to detect previously unreported binding structures.  
We also adapted our glycan microarray to determine HS binding affinity in a high throughput 
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format.  This technique will be highly valuable to academia and industry to rapidly advance 
our understanding of GAG-macromolecule interactions.  Since GAG’s are ubiquitously 
expressed on mammalian cells, GAG mimetics are of increasing interest in drug development 
[102]. Development and utilization of high throughput tools will allow for increased 









HS is a naturally occurring carbohydrate on the exterior of all mammalian cells.  The 
linear polysaccharide is synthesized in the Golgi apparatus by biosynthetic enzymes and 
shuttled to the cell surface attached to proteins as proteoglycans.  HS biosynthetic enzyme 
substrate specificity is a topic that is important to understand the role of specific HS 
structures in biological processes.  In this chapter, we describe a high throughput microarray 
technique that was developed to expedite the understanding of substrate specificity of HS 
biosynthetic enzymes and may also have other applications.  By utilizing high-affinity HS 
ligands, AT and FGF2, we were able to observe the in-situ modification of 
chemoenzymatically synthesized HS attached to a microarray glass surface.  Compounds that 
did not display fluorescence signal before modification displayed fluorescence after 
modification by HS sulfotransferases and PAPS.  Having an increased understanding of 
3OST1, 2OST and Epi can lead to the synthesis of new structures that may have novel 
biological applications.  Simultaneous modification of 96 different glycans using a 
microarray format allows for an increased understanding of carbohydrate-protein interactions 
while using small amount of material.  This technology can be utilized as a useful tool to 
increasing our understanding of HS function and how enzymatic modification can affect 
interactions with proteins. 
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One of HS’s defining characteristics is it’s high negative charge [2].  The charge 
density arises from modification of the HS backbone with sulfo groups as described in 
Chapter 1.  The biosynthesis of HS occurs in the Golgi apparatus via a conserved 3 step 
process: initiation, polymerization and modification [103].  In brief, the HS is elongated with 
repeating GlcA-GlcNAc disaccharide units.  This is referred to as the HS backbone structure.  
The typical length ranges from 50-250 disaccharide units [18].  The last step is modification 
by sulfotransferase or epimerase enzymes.  The GlcNAc can be converted to GlcNS via 
NDSTs and can be further modified to contain 6-O-sulfation and/or 3-O-sulfation utilizing 
other HS sulfotransferases such as 3OST1.  Sulfotransferase enzymes require a sulfo donor 
as a cofactor, which in the case of HS modification is typically PAPS.  The glucuronic acid 
monosaccharide unit can be epimerized via Epi which will produce an IdoA.  The 2-O-
position of both GlcA and IdoA can be sulfated by 2OST, although IdoA is more likely to be 
sulfated.  
 The resulting HS polysaccharides are highly heterogeneous.  This is a result of the 
biosynthetic process not being template driven, there being multiple HS chains per 
proteoglycan and the lengths of the polysaccharides being highly variable.  However, it is 
known that there are specific saccharide sequences that are required for biological activity.  
For example, it has been determined that a HS pentasaccharide sequence is required for 
binding to AT and results in anticoagulant activity [32].  The required pentasaccharide 
sequence is GlcNAc6S-GlcA-GlcNS3S-IdoA-GlcNS.  This HS pentasaccharide binds to AT 
and catalyzes the inactivation of coagulation factor Xa, resulting in decreased clot formation.  
Furthermore, fibroblast growth factor 2 (FGF2) is known to bind heparan sulfate with high 
affinity.  The specific trisaccharide sequence of IdoA2S-GlcNS-IdoA2S has been determined 
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to be the high affinity binding sequence [57].  Other studies have suggested that FGF2 can 
bind GlcNS6S-IdoA2S, albeit with less affinity [104].  Results in Chapter 3 confirmed these 
findings for AT and FGF2. 
 A chemoenzymatic synthesis method has been developed to synthesize specific HS 
oligosaccharide sequences.  This method allows for the control of length and sulfation pattern 
with improved efficiency over chemical synthesis [19].  This method has resulted in a large 
library of compounds with some sequences being scaled up for clinical trials [105].  The 
sulfation patterns that can be produced by chemoenzymatic synthesis are limited by the 
substrate specificity of the enzymes that are used.  For example, 2-O-sulfation of IdoA by 
2OST has an enzyme substrate specificity of which the flanking residues are preferred to be 
GlcNS (without 6S) on the reducing and non-reducing end [43].  Although enzyme substrate 
specificity allows for efficient synthesis of certain saccharide sequences, further 
understanding of substrate specificity will lead to an improved understanding of HS’s 
biological functions. 
 As mentioned above, our previous studies have utilized a large library of 
chemoenzymatically synthesized compounds to construct a HS microarray for investigation 
of HS-Protein interactions [106].  The results were consistent with previous studies and 
positive hit compounds were able to show biological activity without modification.  Herein 
this study, we utilize the microarray technique to modify HS in-situ using biosynthetic 
enzymes and learn about substrate specificity and how enzymatic modification can change 
interactions with proteins.  Specifically, we mix 95 specific compounds with 3OST1 and 
PAPS and probe with fluorescently labeled AT and detect 14 new compounds that bind AT.  
The identified compounds are all 6-O-sulfated and contain IdoA(±2S), which is consistent 
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with known requirements of 3OST1.  In addition, we modify the compounds on the array 
with Epi + 2OST + PAPS and probe with fluorescently labeled FGF2.  The key advantage to 
utilizing the microarray technique is the small amount of material that is required per 
experiment.  Using this technique, we are able to modify compounds while attached to the 
array and determine enzyme substrate specificity and determine how modification with 






Figure 32. Overview of Microarray Modification Assay.  Cartoon schematic of 
modification assay with 3 representative compounds.  (A) Fluorescently labeled 
Antithrombin binding assay before (left) and after 3OST1 modification (right). (B) 
Fluorescently labeled Fibroblast Growth Factor 2 binding assay before (left) and after 
Epi/2OST modification (right).   
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Materials and Methods 
Compound Preparation 
Compounds used on the array were prepared as described in Chapter 2.  To 
summarize, compounds were obtained from a commercially available source 
(www.glycantherapeutics.com).  The compounds came as an azido-tagged oligosaccharide.  
200 µg (1 mg/mL in water) of each oligosaccharide was stirred at room temperature with 
Pd/C in a round bottom flask and was reduced under hydrogen balloon pressure to produce a 
primary amine tag.  The reduction was monitored by ESI-MS and reactions were typically 
complete in 4 hours.  Reductions that were not complete, were allowed to stir overnight, or 
until completion.  The Pd/C was removed by 0.2 µm syringe filter and excess water was 
removed by lyophilization (centrivap).  Dried compounds were dissolved in 50 mM NaPO4 
(pH = 8.5) buffer and stored at -20°C.  Concentrations of final stock solutions were 
determined by fluorescent ninhydrin assay. 
Microarray slide preparation 
Compounds were printed on the array as described in Chapter 2.  Briefly, the amino-
tagged oligosaccharides were spatially arrayed by a S11 robotic arrayer (Scienion) onto an 
NHS-activated glass slide (Nexterion Slide H).  The glass slide is stored at -20°C until 
printing.  Just prior to printing, the slide is allowed to come to room temperature and the 
microarray robotic arrayer delivers picoliters of 12.5 µM oligosaccharide solution from a 384 
well plate to a predetermined place on the glass slide.  The compounds were printed in a 
22x22 format compatible with a 16-well FAST slide multichamber (Figure 33).  5 spots were 
printed per compound.  The 22x22 square was printed on each slide 14 times in a format 
 
94 
compatible with a 16-well-FAST slide incubation chamber (GVS Filter Technology).  After 
printing, the slides were incubated in a humidity chamber overnight.   
 
Figure 33. Layout of microarray library and raw results. (A) Schematic representation of 
microarray library layout.  The compounds are divided into groups based on sulfation 
pattern. Grey = GlcNAc, Red = GlcNS, Blue = GlcNS6S, Purple = IdoA, orange = IdoA2S 
and green = GlcNS6S3S. (B) Raw data of AT hybridization with library.  The results are 
shown before (left) and after (right) modification by 3OST1. (C) Raw data of FGF2 
hybridization with library.  The results are shown before (left) and after (right) modification 
by Epi/2OST. 
After incubation overnight, unreacted oligosaccharides were removed by washing and 
the remaining NHS sites on the glass slide were blocked by ethanolamine (Aldrich).  Slides 
were placed in a 50 mL conical tube containing 50 mL of Ethanolamine solution.  The tube 
was placed in a 50°C water bath for 1 hour.  After 1 hour, slides were washed with water for 
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several minutes and dried by centrifugation.  Slides were stored at room temperature until 
use. 
Enzyme preparation 
Biosynthetic enzymes were prepared as described previously.  3OST1 was 
recombinantly expressed in E. coli (BL21(DE3)RIL) utilizing a Bacterial Expression Plasmid 
(b3-OST-1-pET28) [107].  The enzyme was purified using a nickel nitrilotriacetic acid-
agarose resin (Qiagen) column after sonication utilizing an imidazole gradient from 10-250 
mM.  The collected protein was dialyzed and stored at -80°C in 20 mM Tris buffer (100mM 
NaCl, pH = 7.5). 
Recombinant Epi and 2OST were expressed in SF9 insect cells utilizing Bac-to-Bac 
baculovirus expression system (Invitrogen) [105].  The secreted forms of Epi and 2OST were 
constructed into pFastBac-HT expression vector and infected into cells by recombinant virus.  
After 3-4 days, cultures were harvested and stored at -80°C.  The purification was done using 
an AKTAFPLC system (GE Life Sciences) and Toyopearl AF-heparin HC 650 M column.  
The enzymes were eluted with a linear NaCl gradient from 100 mM to 1000 mM.  Epi and 
2OST were eluted at 500 mM and 750 mM, respectively.  The enzyme fractions were pooled 
stored in 10% glycerol at  -80°C. 
Preparation of fluorescently labeled proteins  
Fluorescently labeled AT and FGF2 were prepared as described previously [106].  
Fluorescently labeled protein was prepared by direct labeling with Alexa Fluor 488 NHS 
Ester (Thermo Scientific, Waltham, MA, USA).  100 µg  of protein was mixed with heparin 
(3 eq), Alexa Fluor 488 NHS Ester (10 eq) and 100 mM NaHCO3.  The reaction proceeds at 
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RT for 1 h. The reaction mixture was purified by heparin column and stored at -80°C in PBS 
buffer. The efficiency of labeling was visualized by fluorescence SDS-PAGE gel.  
Biosynthetic Enzyme Array Modification 
The modification of the microarray chips was achieved by incubating with enzyme(s) 
and PAPS in 20 mM tris buffer with vigorous shaking overnight at room temperature.  For 
3OST1 modification, 1 µg of 3OST1 was mixed with  1 µg PAPS and diluted to 100 µL with 
20 mM tris buffer.  For epi/2OST modification, 1 µg of Epi and 1 µg of 2OST was mixed 
with 1 µg of PAPS and diluted to 100 µL with 20 mM tris buffer.  Tape was placed over the 
well to prevent evaporation while shaking at room temperature overnight.  After shaking, 
water was used to wash the well without removal of the incubation chamber.  After washing 
with water 3 times, 100 µL of a solution containing phosphate-buffered saline with Tween 20 
(PBST)/30% bovine serum albumin (BSA)/1 M NaCl was added to the well and the slide 
was shaken vigorously for 1 hour at room temperature.  After 1 hour of shaking, the well was 
washed with water 3 times again.  The slide now contains modified oligosaccharides and is 
ready for incubation with fluorescently labeled proteins. 
Fluorescently labeled protein hybridization 
Immediately after the modification procedure, 10 μg/mL solution of fluorescently 
labeled protein was prepared by diluting the protein in a PBST/Tris/ BSA solution (PBS, 
0.05% Tween 20, 20 mM Tris, 10% BSA, pH = 7.5). The mixture (100 μL) was placed over 
the arrayed glass slide in a well of the incubation chamber. The hybridization was carried out 
for 1 h in a humidity chamber. The slide was washed by shaking in a PBST solution 




Scanning microarray slides 
Hybridized slides were scanned by a GenePix Pro 4300A scanner (Molecular 
Devices). Slides were scanned using a 488-nm laser and analyzed by GenePix Pro software.  
The PMT Gain setting was set so that 0% of the spots contained saturated pixels.  The mean 
fluorescence intensity (FU) of the 5 spots per compound were determined.  Mean FU ± 
standard deviation (SD) was plotted by compound in GraphPad Prism 8.0. 
[35S] PAPS Radioactivity Assay 
 1 µg of oligosaccharide was mixed with 10 µg of enzyme with ~5000 cpm/µL [35S] 
PAPS and dilute with 20 mM Tris buffer.  The mixture was incubated at 37°C overnight.  
After incubation, the reaction mixture was purified by DEAE column.  UPAS was used to 
stop the reaction and load the oligosaccharide onto the column.  The column was then 
washed three times with 1 mL 250 mM NaCl and the oligo was eluted with 1 M NaCl.  The 
[35S] counts were measured by a liquid scintillation analyzer (Packard).  The results are 
reported as normalized mean ± SD (n=2).  The results are normalized to the highest mean of 
the eleven samples. 
 
Results 
Expanded HS microarray library and L-N623 Naming System 
The array library used in this study was previously described in Chapter 2.  One 
compound has been added to the library with the structure GlcA-GlcNAc6S-GlcA-GlcNS6S-
IdoA2S-GlcNS6S3S-GlcA-R and is referred to as 7-2311’.  The order that the compounds 
are presented in Chapters 2 and 3 consisted of 6 groups.  Herein this chapter, we have 
reordered the library for further clarity and expanded the number of groups to 8 based on 
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sulfation pattern (Figure 34).  Previously, we did not distinguish between IdoA(±2S) 
compounds that do or do not contain 6-O-sulfated GlcN.  However, based on our findings in 
this study, it was determined that the presence of 6-O-sulfation clearly differentiated 
enzymatic activity.  The 8 groups of HS oligosaccharides contained in our library are 
summarized in Table 9.  For this array, we have developed an oligosaccharide naming system 
to facilitate our understanding of the microarray results. The naming system is specific to our 
HS array and it should be noted that we are not suggesting this as a general naming of 
glycans at this time. The naming system is referred to as the “L-N623” system. “L” 
represents the length of the compound and can be one or two digits (range: 4-18) followed by 
a hyphen.  After the hyphen is a four-digit code that represents the number of N-sulfations, 6-
O-sulfations, 2-O-sulfations and 3-O-sulfations, respectively.  The first digit after the hyphen 
(‘N’) represents the number of N-sulfations and ranges from 0-9 in this library.  The second 
digit after the hyphen (‘6’) represents the amount of 6-O-sulfations and ranges from 0-6 in 
this library.  The third digit after the hyphen (‘2’) is the amount of 2-O-sulfations (range: 0-7) 
and the last digit (‘3’) is the amount of 3-O-sulfations (range: 0-2). If the compound is in 
Group 4 or 5, it will have a ‘*’ in place of the number of 2-O-sulfations to differentiate it as a 
compound that contains an IdoA residue that is not 2-O-sulfated. As an example of the L-
N623 system, the compound GlcNAc6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-GlcA is referred 




Figure 34. Reordered compound library with additional compound 7-2311.  L-N623 
compound numbering and symbol nomenclature for glycans (SNFG) structures on the 
microarray.  All compounds except heparin are modified at the reducing end to contain an 





Table 9. Summary of HS library contained on the array. 
Group GlcNAc GlcNS GlcNS6S GlcNS6S3S IdoA IdoA2S Length # of Cmpds 
1 (NAc) Yes No No No No No 5-12 6 
2 (NS) Some Yes No No No No 4-12 18 
3 (6S) Some Yes Yes No No No 6-12 23 
4 (IdoA) Some Yes No No Yes No 6-9 9 
5 (IdoA+6S) Some Yes Yes No Yes No 6-9 4 
6 (IdoA2S) Some Yes No No No Yes 6-18 17 
7 (IdoA2S+6S) Some Yes Yes No No Yes 6-12 11 
8 (GlcNS6S3S) Some Yes Yes Yes No Yes 6-12 7 
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Binding to AT before and after 3OST1 Modification 
96 compounds were spatially arrayed on a glass slide at a printing concentration of 
12.5 µM.  The slide was passivated with an ethanolamine solution.  Before modification, the 
microarray library was hybridized with fluorescently labeled AT to establish a baseline 
(Figure 33B, left).  The results were consistent with our previous studies.  Six compounds 
from group 8 displayed a binding signal after hybridization (Figure 2A).  Although these 
compounds varied in length, from 6-mer to 12-mer, they all contained the GlcNR6S-GlcA-
GlcNS6S3S-IdoA2S-GlcNS6S (where R = -Ac or SO3H) pentasaccharide sequence.  The N-
position of the non-reducing end can be either N-acetylated or N-sulfated without affecting 
the ability to bind AT.  This interaction is not based on charge density or level of sulfation.  
For example, compound 7-3320 and 7-3311 are heptasaccharides with 8 total sulfations, 
however AT recognizes 7-3311 and not 7-3320.  Furthermore, 12-6640 has 16 sulfo groups 
and a charge density of 1.3 sulfations per saccharide and does not bind AT (FU = 125 ± 39) 
whereas 6-2311 which has only 7 sulfo groups and a charge density of 1.16 sulfations per 
saccharide shows binding activity (FU = 2080 ± 577) .  The 3-O-sulfation is a critical 
component to binding AT.  However, an oligosaccharide containing 3-O-sulfation is not 
sufficient for binding AT.  The 3-O-sulfation must be in the center position of the 
pentasaccharide.  Compound 7-2311’ was added to the array and provides evidence of this.  
The 3-O-sulfation on this oligosaccharide is on the reducing end of IdoA2S and therefore 
does not contain the specific AT binding pentasaccharide.  The position of the 3-O-sulfation 
has been confirmed by LCMS/MS and NMR (Appendix III).  Compounds that do not contain 




Figure 35. Bar graph of AT binding to microarray before and after modification by 
3OST1.  (A) A total of 10 μg/mL fluorescently labeled AT screened against 96 compounds 
printed at 12.5 μM. The binding threshold for this experiment was 240 FU. (B) 10 μg/mL 
fluorescently labeled AT screened against 95 compounds printed at 12.5 μM after 
hybridization with 10 μg/mL 3OST1 and 10 μg/mL PAPS for 1 hour. The binding threshold 
for this experiment was 250 FU. For bar graphs A and B, each compound was printed 5 times 
per compound. Results are represented as mean ± SD for each printing density (n = 5). The 
compounds are highlighted below by their groups based on sulfation pattern and are 
classified by their L-N623 name below the graph. 
 
Next, recombinantly expressed enzymes were mixed with the array to determine if 
HS oligosaccharides can be modified in-situ by biosynthetic enzymes.  To study this, we 
aimed to modify compounds with 3OST1 and then hybridize with fluorescently labeled AT.  
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We mixed 3OST1 and PAPS in a microarray well and allowed to incubate at room 
temperature overnight.  3OST1 and PAPS were washed and the slide was then hybridized 
with AT.  The results showed that the six compounds that bound before modification retained 
significant fluorescent signal and fourteen additional compounds were able to be observed as 
having AT binding activity.  The fourteen new compounds that bound were from groups 5, 7 
and 8.  All of these groups contain both IdoA(±2S) and GlcNS6S (Table 9).  Groups 1, 2, 3, 4 
and 6 which do not contain 6-O-sulfated oligosaccharides do not show significant signal after 
modification. This finding is consistent with previous results which determined that 3OST1 
requires 6-O-sulfation for modification [108].  In addition to the 6S requirement, IdoA is also 
a requirement for binding AT.  No compounds in group 3, all of which contain 6-O-sulfation, 
are able to bind AT before or after modification.  Based on our findings being consistent with 
previous studies of 3OST1 substrate specificity, it is clear that the microarray modification 
was able to selectively modify compounds on the solid surface.  Additionally, the modified 
compounds were able to specifically recognize AT if the 3OST1 modification resulted in the 
critical 3-O-sulfation in the center position of the AT binding pentasaccharide. 
 To further our confidence in the modification studies, we selected a series of eleven 
7-mers with representation of each sulfation pattern group.  We mixed these compounds with 
3OST1 and [35S] PAPS and detected covalent modification by a scintillation counter.  What 
we observed was consistent with previous findings; only 6-O-sulfated oligos displayed high 
radioactivity (Figure 36B).  A partially 6-O-sulfated oligosaccharide (Cmpd 7-3100) is 
analyzed and does not show radioactivity.  This indicated that either the level of 6-O-
sulfation or the position of the 6-O-sulfo group is important for the substrate specificity of 
3OST1.  Of note, compound 7-3300 shows modification by radioactivity.  However, even 
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though this compound is able to be modified by 3OST1, the modified version would not be 
able to bind AT.  Therefore, the microarray method is not suitable to detect these 
modifications at this time.  Instead, what this method is capable of detecting is how 
biosynthetic enzymes are able to modify specific HS sequences to change their interaction 
with proteins in a high throughput fashion, while using very small amounts of material. 
 There are 3 other interesting findings determined by the 3OST1+AT experiments.  As 
we have established, there are clear substrate preferences for modification by 3OST1 and 
binding to AT.  The compound must be 6-O-sulfated and contain IdoA(±2S).  Compound 7-
3320 meets both of these requirements; it has three 6-O-sulfations and two IdoA2S residues.  
When tested with [35S] PAPS, the compound shows an ability to be modified by 3OST1 
(Figure 36B).  However, the substrate specificity of 3OST1 requires that a GlcNS6S residue 
be modified on the reducing end of a GlcA.  There is only one position on the non-reducing 
end that we would expect to be modified under those requirements and therefore would not 
produce the AT binding pentasaccharide.  7-3320 is the only compound in group 7 that does 
not show binding of AT after modification (Figure 35B).  This result shows that it is not 
enough for a compound to be able to be modified by an enzyme to show activity in this 
assay.  Instead, the compound must be modified at a specific position that forms the specific 
saccharide binding sequence to be determined as a positive hit. 
 The enzymatic modification microarray study was also able to show that the IdoA 
residue in the AT binding pentasaccharide is not required to be 2-O-sulfated to recognize AT.  
This result is consistent with previous findings [85].  Before modification, all 3-O-sulfated 
compounds in group 8 contain at least one IdoA2S residue.  Therefore, without further 
analysis, we may be led to conclude that 2-O-sulfation is a requirement for binding AT.  
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However, after modification, the four compounds in group 5 display fluorescence signal 
(Figure 35B).  These compounds range from 6-mer to 9-mer but are all able to be modified 
by 3OST1 to form the AT binding pentasaccharide and recognize AT.  Although the library 
of compounds on the array are the largest and most diverse library of specific HS 
oligosaccharides that has been prepared for microarray analysis, the biosynthetic enzyme 
array modification technique is able to further our understanding of HS-protein interactions. 
 Compound 7-2311’ is 3-O-sulfated at the reducing end GlcN and therefore does not 
contain the AT binding pentasaccharide.  Before modification, this compound does not show 
binding with AT (7 ± 6 FU).  After modification by 3OST1, 7-2311’ shows the highest 
fluorescence signal (17564 ± 2977 FU).  In Chapter 3, we described a high throughput 
microarray binding affinity assay and showed that fluorescence intensity is not linearly 
related with binding affinity[106].  Therefore, it is possible that 7-2311’ - which would 
contain two 3-O-sulfations after 3OST1 modification - could have a high binding affinity but 
further studies would be needed to confirm.  By utilizing this modification assay method, we 
were able to expand our understanding of the interaction of HS with AT utilizing a 
microarray technique.  Our results are consistent with previous findings that 3OST1 is an 
enzyme that is able to produce the AT binding pentasaccharide, 6-O-sulfation is required for 
AT binding and the IdoA can be either 2-O-sulfated or not.  These findings were supported 
by a classic [35S] radioactivity study but required ~10,000x more oligosaccharide per 
experiment.  These findings give us confidence that this assay is robust and can be applied to 
other enzyme/protein pairs. 




Figure 36. Comparision of 7mers with AT before and after modification and 
radioactivity measurements.  Eleven 7-mers were selected for analysis by radioactive 
modification with 3OST1 and [35S] PAPS. (A) The 7-mers are represented by their SNFG 
format.  The fluorescence intensity vs compound bar graphs have been extrapolated from 
Figure 2. (B) 1 µg of each oligosaccharide was modified with 10 µg/mL 3OST1 and  [35S] 
PAPS.  The results are displayed as mean normalized cpm ± standard deviation (n=2) vs 
compound.  The results are normalized to the mean activity of compound 7-2311.   
Binding to FGF2 before and after Epi/2OST Modification 
To assess the ability of the modification assay to be applied to other HS biosynthetic 
enzymes, we sought to modify the array with Epi and 2OST and probe with FGF2 (Figure 
32B).  Before modification, we are able to determine that IdoA2S is required for binding 
FGF2 (Figure 37A).  With further analysis, we determined that 6-O-sulfation also plays a 
role in increasing the observed fluorescence intensity.  Compounds in group 6 do not contain 
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6-O-sulfation but do contain IdoA2S.  There is a significant difference in the fluorescence 
intensity of compounds with one IdoA2S when compared to compounds with two or more 
IdoA2S.  For example, 8-4010 has a mean fluorescence signal that is 3.5x less than 8-4020 
(1043 ±107 FU vs 3608 ± 942 FU, respectively).  Similar trends can be seen for 7-3010 vs 7-
3020 and 9-4010 vs 9-4020.  Based on our microarray findings, we observe that compounds 
that contain more IdoA2S show higher signal.  18-9070 contains seven IdoA2S residues and 
displays the highest fluorescence signal (FU = 19393 ± 1087).  However, when an 8-mer 
with one IdoA2S also contains 6-O-sulfation, i.e. 8-4410, the fluorescence intensity is similar 
to a similar compound with two IdoA2S (Cmpd 8-4410 = 3446 ± 801 FU).  Previous studies 
have shown that the preferred HS substrate for FGF2 is a trisaccharide that contains the 
sequence IdoA2S-GlcNS-IdoA2S [57], which would require two or more IdoA2S residues to 
be present for binding.  However, other crystal structure studies have found that there is an 
alternative mode of binding with only one IdoA2S [104].  More recently, Yi-Ching Li and 
colleagues studied the 48 possible disaccharides and determined the importance of GlcNS-
IdoA2S for binding FGF2 [109].  In addition, their disaccharide studies showed that 6S was 
able to coordinate additional FGF2 proteins at an allosteric site.  We can observe compounds 
that have IdoA-GlcNS6S and although the signal is above the binding threshold (240 FU), 
it4is significantly lower than compounds that contain 2-O-sulfation (i.e. 9-44*0 = 572 ± 26 
FU vs 9-4410 = 3600 ± 860 FU).  From these observations, compounds without 2-O-





Figure 37. Bar graph representation of FGF2 hybridization with microarray before and 
after Epi/2OST modification.  (A) A total of 10 μg/mL fluorescently labeled FGF2 
screened against 96 compounds printed at 12.5 μM. The binding threshold for this 
experiment was 250 FU. (B) 10 μg/mL fluorescently labeled FGF2 screened against 95 
compounds printed at 12.5 μM after hybridization with 10 μg/mL Epi, 10 μg/mL 2OST and 
10 μg/mL PAPS for 1 hour. The binding threshold for this experiment was 240 FU. For bar 
graphs A and B, each compound was printed 5 times per compound. Results are represented 
as mean ± SD for each printing density (n = 5). The compounds are highlighted below by 
their groups based on sulfation pattern and are classified by their L-N623 name below the 
graph. 
 
 After we established the baseline characteristics of FGF2 binding on the microarray, 
we modified the library of compounds using Epi, 2OST and PAPS.  This resulted in 4 types 
 
109 
of compounds being modified and able to bind FGF2 (Figure 37B).  The first type of 
compounds that was modified was group 2 compounds that contain NS, but not 6S.  9-2000 
only has one GlcA position of which can be modified to IdoA2S. But as mentioned 
previously, compounds with more than one IdoA2S show the highest fluorescence signal and 
therefore 9-2000 does not show a signal that is greater than the binding threshold (Cmpd 9-
2000 = 168 ± 77 FU).  Cmpd 7-3000 has two GlcA positions that can be modified a signal of 
3257 ± 506 FU after modification was observed.  The preferred substrate specificity of 2OST 
is GlcA-GlcNS-GlcA-GlcNS [43].  However, there is slight modification of GlcNS-GlcA-
GlcNS on the nonreducing end of the structure.  Therefore, 8-3000 which contains both of 
these types of GlcA shows a fluorescence signal of 428 ± 285 FU.  However, if the length of 
the compound is extended by 1 residue, there are now two preferred substrate GlcA residues 
that can be modified.  9-3000 displays a binding signal of 1675 ± 437 FU which is 
significantly greater than the binding threshold.  Similar to the findings before modification, 
fully N-sulfated compounds with greater length show a higher mean fluorescence signal after 
modification (6-3000 < 7-3000 < 8-4000 < 9-4000 < 12-6000). 
Additionally, several group 3 compounds are able to be modified.  It has previously 
been shown that 6S inhibits the modification by 2OST [43].  However, some of the 
compounds on the array are only partially 6-O-sulfated.  Therefore, compounds like 7-3100 
can be modified and show significant binding signal after modification (before = 206 ± 20 
FU vs after = 1524 ± 266 FU).  A similar compound with just one additional 6-O-sulfation 
shows a decreased binding signal that is close to the binding threshold (7-3200 = 349 ±72).  
From this finding, it is clear that there is a preferred 2OST substrate specificity for modifying 
HS.  Although 6-O-sulfation is known to inhibit 2OST modification, this assay is sensitive 
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enough to detect that only 6-O-sulfation that is proximal to the modification site inhibits the 
enzymatic activity. 
Group 4 compounds contain IdoA but have not been 2-O-sulfated prior to the 
modification assay.  In our initial screen we observed that the 2-O-sulfation is critical to 
binding FGF2.  After Epi/2OST modification, we are able to learn more about the binding 
preferences of FGF2.  As we observed in group 3 compounds, the ability of two sites to be 
modified by 2OST is important for showing strong activity after modification.  Cmpd 6-30*0 
displays minimal FGF2 binding after treatment with 2OST (413 ± 90 FU).  Cmpd 7-30*0 is 
one residue longer than 6-30*0 and therefore is a better substrate for 2OST and displays an 
FGF2 binding signal of 2066 ± 417 FU after modification.  Also similar to group 3 findings, 
the longer compounds show a higher binding signal (8-40*0 = 3779 ± 589 and 9-40*0 = 
5165 ± 1741).   
Non-6-O-sulfated compounds that are already installed with IdoA2S (Group 6) show 
a shift in signal if they are long enough and do not have inhibitory GlcNAc residues [43].  
This is presumably due to the installation of additional IdoA2S residues.  As an example, the 
signal of 9-2010 remains low before and after modification (610 ± 74 FU and 637 ± 29 FU, 
respectively).  However, when the N-sulfo content is increased from 2 to 4, the binding signal 
of 9-4010 after modification increases to 5348 ± 1604 FU.  Another interesting finding is that 
9-4020 has additional observed signal after modification.  Before modification, the observed 
9-4020 signal is 3217 ± 1386 FU and after modification is 8324 ± 2238 FU.  Because the 
binding signal of 9-4020 is significantly greater than 9-4010 after modification (p<0.05), this 
suggests that the enzymatic modification is incomplete.  We are unable to assess the degree 
of completion of the enzymatic modification on the array at this time.  However, it is 
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reasonable to assume that going from one IdoA2S to three IdoA2S residues is less efficient 
than starting with two IdoA2S residues. 
 
 
Figure 38. Analysis of a select series of 7-mers and radioactivity measurements of 
Epi/2OST modification.  Eleven 7-mers were selected for analysis by radioactive 
modification with Epi/2OST and [35S] PAPS. (A) The 7-mers are represented by their SNFG 
format.  The fluorescence intensity vs compound bar graphs have been extrapolated from 
Figure 4. (B) 1 µg of each oligosaccharide was modified with 10 µg/mL 3OST1 and  [35S] 
PAPS.  The results are displayed as mean normalized cpm ± standard deviation (n=2) vs 
compound.  The results are normalized to the mean activity of compound 7-3100.   
 
Lastly, we conducted the classic radioactivity assay with Epi + 2OST to confirm the 
findings from the microarray modification study.  As observed previously, compounds 7-
3000, 7-3100, 7-30*0 and 7-3010 all show a shift in fluorescence intensity from before 
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modification to after (Figure 38A).  Additionally, these compounds show a significant 
radioactivity signal, indicating that they are able to be modified, as predicted by the 
modification assay.  Compound 7-0000 does not show a change in fluorescence intensity nor 
radioactivity after modification by Epi/2OST indicating the importance of N-sulfation for 
modification by 2OST.  All compounds with three 6-O-sulfations do not show activity in the 
radioactivity assay which is consistent with previous reports on 2OST substrate specificity.  
Interestingly, compound 7-3100 contains partial 6-O-sulfation and demonstrates an ability to 
be sulfated by 2OST.  This is consistent with the observations in the microarray modification 
experiments.  Finally, 7-33*0 shows a slight increase in fluorescence signal after 
modification.  However, based on the radioactivity assay, it is clear that this compound is not 
being 2-O-sulfated to increase the binding to FGF2.  We believe that this may be due to the 
ability of FGF2 to bind weakly to compounds which contain the IdoA-GlcNS6S disaccharide 
motif.   
 
Discussion 
 HS is a highly heterogeneous polysaccharide.  These heterogenous mixtures are the 
product of biosynthetic enzymes that produce specific modifications within a HS 
polysaccharide.  In several instances, specific sulfation patterns have been determined to 
influence biological activity.  These specific saccharide sequences have been shown to have 
biological activity with therapeutic potential in many disease states, including 
anticoagulation, cancer, infectious disease, inflammation and more [110].  Although the 
modification process is not template driven, different tissues have variable expression of the 
biosynthetic machinery required for producing specific saccharide sequences.  However, due 
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to the heterogeneity of these molecules and the inefficiency of chemical synthesis, the study 
of specific saccharide sequences required for biological activity has been limited.  With the 
advantage of requiring small amounts of material, the microarray technique provides an 
opportunity to further our understanding of these interactions with the hope of developing 
beneficial therapeutics for patients in need. 
 In Chapters 2 and 3, we demonstrated the value of combining the efficiency of 
chemoenzymatic synthesis with the microarray technique to improve our understanding of 
HS-protein interactions.  In addition to developing a method that determined which 
compounds can bind, we also demonstrated a technique that could determine how tightly the 
compounds bind to a protein.  In this chapter, we furthered the capabilities of the microarray 
technique to improve our understanding of HS-protein interactions.  To accomplish this, we 
hybridize the array, which contains 95 specific HS oligosaccharides, with biosynthetic 
enzymes and subsequently probe the modifications with fluorescently labeled proteins 
(Figure 32).  Based on this technique, we are able to learn about the substrate specificity of 
the biosynthetic enzymes as well as how the modification of HS structures by these enzymes 
affects the interaction with proteins.  We then confirm these studies utilizing classic 
radioactivity measurements which utilizes a radiolabeled sulfo donor, [35S] PAPS. 
 The substrate specificity of 3OST1 has been previously studied [48].  Therefore, we 
chose this as a model system to test the capabilities of modifying chemoenzymatically 
synthesized HS oligosaccharides in a high throughput microarray format.  Before 
modification, the array library contains six compounds that display fluorescence signal upon 
hybridization with AT.  All six compounds contain the AT binding pentasaccharide 
sequence.  After modification, there are fourteen additional compounds on the array that are 
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able to recognize AT.  The compounds that are modified all have similar sulfation patterns 
and are able to produce the AT binding pentasaccharide.  The addition of a 3-O-sulfo group 
on the central GlcN of a GlcNR6S-GlcA-GlcNS6S-IdoA(±2S)-GlcNS6S sequence is 
consistent with the known requirements of 3OST1.  The requirements have been reported to 
be specific for a 6-O-sulfated GlcN residue that is proximal to a GlcA.  Cmpd 7-3320 
contains both 6-O-sulfation and IdoA2S and is able to be sulfated by 3OST1 (Figure 36B).  
However, 7-3320 cannot form the pentasaccharide and therefore does not show activity in 
this assay.  We recently engineered a triple mutant 6-O-sulfotransferase that can selectively 
sulfate specific positions on the oligosaccharide [29].  The mutant enzyme and other 
developments will allow for expansion of the microarray library and further understanding of 
the substrate specificity of HS enzymes.  7-2311’ contains 3-O-sulfation prior to 
modification, but not at the central GlcN required for binding AT.  After modification, 7-
2311’ displays the highest fluorescence signal in this assay.  In addition, group 5 compounds 
that do not contain 2-O-sulfation are able to show activity in this assay.  This is consistent 
with previous findings that 2-O-sulfation is not required for 3OST1 modification or AT 
binding [85]. 
 The findings from our new HS microarray technique were consistent with previous 
literature.  However, we wanted to confirm our findings that the compounds we observed 
were indeed able to be modified by 3OST1.  The most valuable advantage of utilizing the 
microarray technique is the ability to utilize very small amounts of material for each 
experiment.  Previous studies have shown that about 10 pg of material are contained within 
each spot on our microarray [82].  For each experiment, a total of 10 spots per compounds (5 
spots for before modification and 5 spots for after modification).  This means that only about 
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100 pg of material are used.  In comparison, a relatively sensitive method of enzymatic 
activity is radiometric measurements [111].  For each compound, 1 µg of oligosaccharide 
was used per experiment.  This is a 10,000-fold difference in oligosaccharide required.  
Additionally, 10x the amount of enzyme was required for a single compound to produce 
significant results.  Since each compound must be modified and purified individually, this 
would require 960x the amount of enzyme used to determine substrate specificity for the 96 
compounds in this library.  Utilizing the microarray technique is a highly efficient and high 
throughput method for understanding how HS biosynthetic enzymes alter the ability of 
compounds to bind proteins. 
 Since the results with 3OST1 and AT were consistent with our previous 
understanding of 3OST1 modification and AT binding, we decided to test our assay utilizing 
Epi/2OST and FGF2.  Epi and 2OST are known to co-localize in biological systems and are 
thought to act in a coordinated fashion [42].  The requirement of IdoA2S was displayed in 
the microarray format by only showing fluorescent signal with compounds in groups 6-8 
prior to Epi/2OST modification (Figure 37A).  There is minimal fluorescence signal 
observed for compounds in group 5.  Group 5 compounds contain IdoA (without 2S) and 
GlcNS6S.  Previous crystallography studies suggest that 2-O-sulfation is not required for 
FGF2 binding [104].  Oligosaccharides that contain IdoA-GlcNS6S disaccharides are able to 
bind FGF2, but the signal is weak (< 600 FU) in this assay and therefore a meaningful 
conclusion cannot be drawn here.  Also, before modification there is a clear dependence on 
the number of IdoA2S contained within the structure.  Within group 6, compounds without 6-
O-sulfation and only one IdoA2S show relatively low signal.  As you increase the number of 
IdoA2S within the individual structure, an increase in fluorescence signal is observed.  The 
 
116 
18-mer with 7 IdoA2S residues, 18-9070, has the highest observed signal before and after 
modification.   
Interestingly, group 7 compounds with only one IdoA2S residue but are fully 6-O-
sulfated display a similar fluorescence signal to group 6 compounds which contain multiple 
IdoA2S residues and do not contain 6-O-sulfation.  These findings may be due to the ability 
for HS to dimerize FGF2 or perhaps may be due to binding affinity.  It is possible that 
compounds with multiple IdoA2S residues can bind with higher affinity, this is certainly 
consistent with our microarray binding affinity studies.  That being said, it is also possible 
that 6-O-sulfated compounds can bind with less affinity but have the ability to dimerize 
FGF2.  A single oligosaccharide with multiple proteins bound would be expected to display 
an increased fluorescence intensity.  It is difficult to conclude anything about the 
dimerization or binding affinity based on a single concentration measurement.  Further 
analysis, which requires much more oligo and protein, would be needed to make definitive 
statements on the ability of certain proteins to dimerize or tightly bind HS compounds.  This 
assay is not intended to be a definitive in it’s findings.  Alternatively, it is intended to be used 
as a screening method to identify compounds that can bind proteins and other techniques can 
be utilized to confirm the finding of this assay. 
After modification by Epi, 2OST and PAPS, the microarray provided insights to the 
substrate specificity of 2OST and FGF2.  It is clear that group 3 compounds that contain high 
levels of 6-O-sulfation are not able to recognize FGF2 after hybridization with Epi, 2OST 
and PAPS.  This finding is consistent with previous reports of 2OST substrate specificity 
[43].  Before modification, we observed that FGF2 was able to bind 6-O-sulfated 
oligosaccharides, sometimes even with increased signal compared to similar compounds 
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without 6-O-sulfation.  Therefore, the observation that compounds in group 2, 4 and 6 which 
are not 6-O-sulfated are able to recognize FGF2 after modification indicates the substrate 
specificity of 2OST.  Some partially 6-O-sulfated compounds in group 3 are able to be 
modified to recognize FGF2.  After analysis of the partially 6-O-sulfated compounds that are 
able to be modified, it is clear that the compounds that are modified contain at least one GlcA 
residue with the preferred substrate motif of GlcA-GlcNS-GlcA-GlcNS.  For example, 7-
3100 has the structure GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS6S-GlcA-R.  With the 
addition of an additional 6-O-sulfation, 7-3200 has the structure GlcA-GlcNS-GlcA-
GlcNS6S-GlcA-GlcNS6S-GlcA-R.  This compound displays a significantly lower FGF2 
binding signal after Epi/2OST modification.  Based on these results, we are able to confirm 
previous findings about 2OST modification in addition to FGF2 substrate recognition. 
In conclusion, we have developed a high throughput screening tool utilizing a 
microarray technique to identify compounds that can be modified by biosynthetic enzymes to 
recognize proteins.  After modification by 3OST1, we identified fourteen new binding 
compounds that were not able to be identified prior to 3OST1 modification.  Four of these 
compounds are expected to produce compounds that are on the array prior to modification, 
but ten of the new compounds are expected to produce additional structural motifs that were 
not part of the library.  Similarly, modification by Epi/2OST was able to increase the 
diversity of compounds on the array and increase the number of compounds that bind FGF2.  
This technique expands the compounds on the array which will lead to improved 
understanding of HS-protein interactions as well as improved understanding of how 
biosynthetic enzymes modify HS and modulate biological activity.  We believe that this 
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technique will be beneficial to academia and industry and hopefully lead to beneficial 





















1 GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1183.05 1182.6 1157.05 1156.8
2 GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1386.24 1385.8 1360.24 1360
3 GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1562.36 1561.8 1536.37 1535.8
4 GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1765.56 1765.2 1739.56 1740
5 GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1941.68 1941.6 1915.68 1915.5
6 GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 2524.19 * 2498.2 2497.65
7 GlcNS-GlcA-GlcNS-GlcA-R 1082.96 1082.6 1056.96 1056.6
8 GlcA-GlcNS-GlcA-GlcNS-GlcA-R 1259.09 1259.1 1233.09 1233
9 GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1424.26 1425 1398.26 1399.5
10 GlcNS-GlcA-GlcNS-GlcA-GlcNAc-GlcA-R 1462.28 1462.5 1436.28 1436.4
11 GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-R 1500.3 1500.3 1474.3 1474.5
12 GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1600.38 1600.8 1574.39 1575
13 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNAc-GlcA-R 1638.4 1638.6 1612.41 1612.8
14 GlcA-GlcNAc-GlcA-GlcNS-GlcA-GlcNS-GlcA-R 1638.40 1638.3 1612.41 1612.2
15 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-R 1676.42 1676.1 1650.43 1650.6
16 GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1803.58 1803.3 1777.58 1777.5
17 GlcNS-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1841.6 1842 1815.6 1815.9
18 GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNAc-GlcA-R 1879.62 1880.4 1853.62 1855.2
19 GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-R 1917.64 1917.2 1891.64 1891.6
20 GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 1979.7 1979.4 1953.7 1953.3
21 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-R 2017.72 2017.8 1991.72 1992
22 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNAc-GlcA-R 2055.74 2056.2 2029.74 2028
23 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-R 2093.76 2093.2 2067.76 2067.6
24 GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-R 2752.31 * 2726.32 2726.04
25 GlcNS-GlcA-GlcNS-GlcA-GlcNS6S-GlcA-R 1580.36 1580.8 1554.36 1554.8
26 GlcNS-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 1660.41 1660.8 1634.42 1634.8
27 GlcNS6S-GlcA-GlcNAc6S-GlcA-GlcNAc6S-GlcA-R 1664.43 1664.1 1638.43 1638.3
28 GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNAc6S-GlcA-R 1702.45 1702.8 1676.45 1676.8
29 GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 1740.47 1740.5 1714.47 1715
30 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS6S-GlcA-R 1756.48 1757.2 1730.48 1730.4
31 GlcA-GlcNS-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 1836.54 1837.2 1810.54 1811.2
32 GlcA-GlcNS6S-GlcA-GlcNAc6S-GlcA-GlcNAc6S-GlcA-R 1840.56 1841.6 1814.56 1815.2
33 GlcA-GlcNAc6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 1878.58 1878.4 1852.58 1852.4
34 GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNAc6S-GlcA-R 1878.58 1878.8 1852.58 1852.8
35 GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 1916.6 1917 1890.6 1891.5
36 GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS6S-GlcA-R 1997.7 1998 1971.7 1972
37 GlcNS6S-GlcA-GlcNAc6S-GlcA-GlcNAc6S-GlcA-GlcNAc6S-GlcA-R 2123.81 2123.2 2097.81 2097.6
38 GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNAc6S-GlcA-GlcNAc6S-GlcA-R 2161.83 2161.5 2135.83 2135
39 GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNAc6S-GlcA-R 2199.85 2199.5 2173.85 2173.5
40 GlcNS-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 2157.81 2158.5 2131.81 2132
41 GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 2237.87 2237 2211.87 2211.5
42 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS6S-GlcA-R 2173.82 2174 2147.82 2148
43 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 2253.88 2253.5 2227.88 2227.5
44 GlcA-GlcNS-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 2333.93 2333 2307.94 2308
45 GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNAc6S-GlcA-GlcNAc6S-GlcA-R 2337.95 2338.5 2311.95 2312
46 GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-R 2413.99 2413 2387.99 2387.5




















48 GlcNAc-GlcA-GlcNS-IdoA2S-GlcNS6S-GlcA-R 1542.34 1542.6 1516.34 1516.5
49 GlcNS-GlcA-GlcNS-IdoA2S-GlcNS6S-GlcA-R 1580.36 1579.5 1554.36 1554
50 GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 1820.53 1820.8 1794.53 1794.8
51 GlcA-GlcNAc-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 1718.46 1719.6 1692.46 1692.8
52 GlcA-GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 1756.48 1755.6 1730.48 1730.1
53 GlcA-GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 1996.65 1995.6 1970.65 1970
54 GlcA-GlcNAc6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 1958.63 1958.4 1932.63 1932.4
55 GlcA-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcA-R 1836.54 1836.8 1810.54 1810.4
56 GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 2076.71 2076.5 2050.71 2051
57 GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 1921.66 1922.1 1895.66 1896
58 GlcNAc-GlcA-GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 1959.68 1959 1933.68 1933.2
59 GlcNS-GlcA-GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 1997.7 1997.2 1971.7 1971.2
60 GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 2317.92 2317.5 2291.93 2291
61 GlcNAc-GlcA-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcA-R 2039.73 2040 2013.73 2014.4
62 GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcA-R 2077.75 2077.5 2051.75 2051.5
63 GlcNAc6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 2359.96 2359 2333.96 2334
64 GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 2397.98 2397.5 2371.98 2371.5
65 GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 2097.78 2098 2071.78 2072.4
66 GlcA-GlcNAc-GlcA-GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 2135.8 2135.6 2109.8 2109.6
67 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-R 2173.82 2173.2 2147.82 2147.2
68 GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 2494.05 2493.5 2468.05 2467.5
69 GlcA-GlcNAc-GlcA-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcA-R 2215.86 2216 2189.86 2190.4
70 GlcA-GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcA-R 2253.88 2254 2227.88 2228.4
71 GlcA-GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 2574.1 2574.5 2548.11 2548.5
72 GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcA-R 3072.54 * 3046.54 3046.2
73 GlcNAc6S-GlcA-lcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 3514.86 * 3488.87 3488.48
74 GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 3552.88 * 3526.89 3526
75 GlcNS-GlcA-GlcNS-IdoA2S- GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-IdoA2S- GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-IdoA2S-GlcNS-GlcA-R 4564.73 * 4538.73 4537.26
76 GlcNAc6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-R 1862.57 1862.4 1836.57 1836.8
77 GlcNS6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-R 1900.59 1900.8 1874.59 1874.4
78 GlcA-GlcNS6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-R 2076.71 2076 2050.71 2050
79 GlcNAc6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 2440.02 2439.5 2414.02 2413
80 GlcNS6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 3632.94 * 3606.94 3606.72
81 GlcNS6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S3S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-R 3713 * 3687 3685.68
82 GlcNAc-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 1462.28 1462.5 1436.28 1436.7
83 GlcNS-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 1500.3 1500.9 1474.3 1474.2
84 GlcNS6S-GlcA-GlcNS6S-IdoA-GlcNS6S-GlcA-R 1740.47 1740.5 1714.47 1715
85 GlcA-GlcNAc-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 1638.4 1638 1612.41 1612.2
86 GlcA-GlcNS-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 1676.42 1675.8 1650.43 1650.3
87 GlcA-GlcNS6S-GlcA-GlcNS6S-IdoA-GlcNS6S-GlcA-R 1916.6 1917 1890.6 1891
88 GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 1841.6 1841.1 1815.6 1815.3
89 GlcNAc-GlcA-GlcNS-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 1879.62 1879.6 1853.62 1854
90 GlcNS-GlcA-GlcNS-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 1917.64 1917.2 1891.64 1891.2
91 GlcNAc6S-GlcA-GlcNAc6S-GlcA-GlcNS6S-IdoA-GlcNS6S-GlcA-R 2161.83 2161 2135.83 2135.5
92 GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 2017.72 2017.6 1991.72 1991.6
93 GlcA-GlcNS-GlcA-GlcNS-GlcA-GlcNS-IdoA-GlcNS-GlcA-R 2093.76 2093.2 2067.76 2067.6
94 GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-IdoA-GlcNS6S-GlcA-R 2413.99 2413.8 2387.99 2388
H HEPARIN n.d. n.d. n.d. n.d.
* = Only the final product (amino) was determined.                                     R = N -(6-aminohexanamidyl) p -aminophenyl or N -(6-azidohexanamidyl) p -aminophenyl
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APPENDIX II. STOCK SOLUTION CONCENTRATION DETERMINATION. 
Cmpd # [Ninhydrin] ± SD (µM) Dilution factor [Stock] (µM) 
1 18.8 ± 1.0 5 94 
2 22.2 ± 1.9 20 443 
3 15.1 ± 3.7 20 302 
4 10.6 ± 0.7 10 106 
5 79.6 ± 2.0 10 796 
6 7.7 ± 0.9 10 77 
7 44.8 ± 0.1 10 448 
8 21.6 ± 4.1 10 216 
9 15.0 ± 2.3 10 150 
10 14.8 ± 1.4 5 74 
11 21.6 ± 1.6 33 720 
12 123.9 ± 85.5 5 619 
13 72.6 ± 2.6 5 363 
14 45.3 ± 0.4 10 453 
15 22.5 ± 0.3 5 113 
16 17.3 ± 0.9 5 87 
17 11.5 ± 1.1 5 58 
18 7.7 ± 2.2 5 39 
19 21.4 ± 0.6 10 214 
20 21.2 ± 3.8 5 106 
21 9.0 ± 1.2 5 45 
22 19.2 ± 2.7 5 96 
23 22.3 ± 0.2 10 223 
24 8.7 ± 1.2 20 173 
25 10.6 ± 2.4 5 53 
26 34.9 ± 0.6 5 175 
27 44.0 ± 1.2 10 440 
28 8.6 ± 1.9 5 43 
29 27.0 ± 2.2 5 135 
30 10.6 ± 0.5 5 53 
31 8.1 ± 0.4 5 40 
32 14.4 ± 2.0 5 72 
33 16.7 ± 0.2 5 84 
34 18.2 ± 1.6 5 91 
35 7.7 ± 1.4 5 39 
36 9.0 ± 0.1 5 45 




Cmpd # [Ninhydrin] ± SD (µM) Dilution factor [Stock] (µM) 
38 42.4 ± 6.0 5 212 
39 16.9 ± 0.7 20 339 
40 21.9 ± 3.9 5 109 
41 21.9 ± 1.8 5 110 
42 16.9 ± 2.1 5 85 
43 100.0 ± 0.7 5 500 
44 17.0 ± 0.1 5 85 
45 15.5 ± 1.3 5 78 
46 23.8 ± 1.4 5 119 
47 6.2 ± 0.5 20 124 
48 11.2 ± 2.5 5 56 
49 14.7 ± 3.2 5 74 
50 11.1 ± 1.0 5 56 
51 7.9 ± 0.7 5 39 
52 13.4 ± 2.9 10 134 
53 17.4 ± 0.1 5 87 
54 10.2 ± 0.2 5 51 
55 12.2 ± 1.8 5 61 
56 20.0 ± 3.0 5 100 
57 13.0 ± 1.7 5 65 
58 8.8 ± 0.9 5 44 
59 16.9 ± 2.4 5 85 
60 16.3 ± 1.4 5 81 
61 16.9 ± 0.4 5 85 
62 111.6 ± 0.4 5 558 
63 53.2 ± 0.5 5 266 
64 30.6 ± 0.9 5 153 
65 10.4 ± 0.7 5 52 
66 9.3 ± 1.1 5 47 
67 12.7 ± 1.9 5 64 
68 18.0 ± 2.7 5 90 
69 10.8 ± 0.4 5 54 
70 12.6 ± 1.2 5 63 
71 8.5 ± 1.1 5 43 
72 6.4 ± 0.4 20 128 
73 5.5 ± 0.6 20 110 
74 2.0 ± 0.2 20 41 
75 7.7 ± 1.2 20 153 




Cmpd # [Ninhydrin] ± SD (µM) Dilution factor [Stock] (µM) 
77 17.9 ± 5.8 5 89 
78 9.2 ± 1.4 5 92 
79 25.0 ± 0.6 5 125 
80 7.1 ± 0.6 20 142 
81 6.7 ± 1.2 20 134 
82 16.9 ± 0.9 5 84 
83 19.4 ± 1.9 5 97 
84 12.1 ± 0.9 5 60 
85 108.0 ± 2.0 5 540 
86 16.9 ± 3.7 5 84 
87 19.1 ± 4.0 5 95 
88 33.8 ± 4.4 10 338 
89 10.0 ± 1.0 5 50 
90 26.8 ± 0.5 5 134 
91 18.9 ± 2.3 10 189 
92 36.7 ± 0.6 10 367 
93 44.6 ± 1.6 5 223 
94 7.8 ± 1.3 10 78 





APPENDIX III. HS LIBRARY CHARACTERIZATION. 




































Azido Molecular Weight = 1183.05 Da 


































Amino Molecular Weight = 1157.05 Da 
Amino ESI-MS observed m/z: 577.4 [M-2H]2- 
 














































Azido Molecular Weight = 1386.24 Da 






































Amino Molecular Weight = 1360.24 Da 
Amino ESI-MS observed m/z: 679.0 [M-2H]2- 
 




















































Azido Molecular Weight = 1562.36 Da 













































Amino Molecular Weight = 1536.37 Da 
Amino ESI-MS observed m/z: 766.9 [M-2H]2- 
 























































Azido Molecular Weight = 1765.56 Da 


















































Amino Molecular Weight = 1739.56 Da 
Amino ESI-MS observed m/z: 579.0 [M-3H]3- 
 




























































Azido Molecular Weight = 1941.68 Da 






















































Amino Molecular Weight = 1915.68 Da 
Amino ESI-MS observed m/z: 637.5 [M-3H]3- 
 














































































Azido Molecular Weight = 2524.19 Da 








































































Amino Molecular Weight = 2498.2 Da 
Amino ESI-MS observed m/z: 831.55 [M-3H]3- 
 




































Azido Molecular Weight = 1082.96 Da 






























Amino Molecular Weight = 1056.96 Da 
Amino ESI-MS observed m/z: 527.3 [M-2H]2- 
 









































Azido Molecular Weight = 1259.09 Da 



































Amino Molecular Weight = 1233.09 Da 
Amino ESI-MS observed m/z: 410.0 [M-3H]3- 
 














































Azido Molecular Weight = 1424.26 Da 








































Amino Molecular Weight = 1398.26 Da 
Amino ESI-MS observed m/z: 465.5 [M-3H]3- 
 














































Azido Molecular Weight = 1462.28 Da 








































Amino Molecular Weight = 1436.28 Da 
Amino ESI-MS observed m/z: 486.5 [M-3H]3- 
 














































Azido Molecular Weight = 1500.3 Da 








































Amino Molecular Weight = 1474.3 Da 
Amino ESI-MS observed m/z: 490.5 [M-3H]3- 
 



















































Azido Molecular Weight = 1600.38 Da 














































Amino Molecular Weight = 1574.39 Da 
Amino ESI-MS observed m/z: 524.0 [M-3H]3- 
 


















































Azido Molecular Weight = 1638.4 Da 














































Amino Molecular Weight = 1612.41 Da 
Amino ESI-MS observed m/z: 536.6 [M-3H]3- 
 


















































Azido Molecular Weight = 1638.4 Da 














































Amino Molecular Weight = 1612.41 Da 
Amino ESI-MS observed m/z: 536.4 [M-3H]3- 
 
Additional information:  
http://www.rsc.org/suppdata/c6/cc/c6cc08204a/c6cc08204a1.pdf (pp 19-21)  
 
138 














































Azido Molecular Weight = 1676.42 Da 














































Amino Molecular Weight = 1650.43 Da 
Amino ESI-MS observed m/z: 549.2 [M-3H]3- 
 























































Azido Molecular Weight = 1803.58 Da 


















































Amino Molecular Weight = 1777.58 Da 
Amino ESI-MS observed m/z: 591.5 [M-3H]3- 
 























































Azido Molecular Weight = 1841.6 Da 


















































Amino Molecular Weight = 1815.6 Da 
Amino ESI-MS observed m/z: 604.3 [M-3H]3- 
 























































Azido Molecular Weight = 1879.62 Da 


















































Amino Molecular Weight = 1853.62 Da 
Amino ESI-MS observed m/z: 462.8 [M-4H]4- 
 























































Azido Molecular Weight = 1917.64 Da 


















































Amino Molecular Weight = 1891.64 Da 
Amino ESI-MS observed m/z: 471.9 [M-4H]4- 
 




























































Azido Molecular Weight = 1979.7 Da 






















































Amino Molecular Weight = 1953.7 Da 
Amino ESI-MS observed m/z: 650.1 [M-3H]3- 
 




























































Azido Molecular Weight = 2017.72 Da 






















































Amino Molecular Weight = 1991.72 Da 
Amino ESI-MS observed m/z: 663.0 [M-3H]3- 
 




























































Azido Molecular Weight = 2055.74 Da 






















































Amino Molecular Weight = 2029.74 Da 
Amino ESI-MS observed m/z: 675.0 [M-3H]3- 
 




























































Azido Molecular Weight = 2093.76 Da 






















































Amino Molecular Weight = 2067.76 Da 
Amino ESI-MS observed m/z: 515.9 [M-4H]4- 
 





Compound #24 (12-6000) 
 







































































Azido Molecular Weight = 2752.31 Da 








































































Amino Molecular Weight = 2726.32 Da 
Amino ESI-MS observed m/z: 680.51 [M-4H]4- 
 














































Azido Molecular Weight = 1580.36 Da 








































Amino Molecular Weight = 1554.36 Da 
Amino ESI-MS observed m/z: 387.7 [M-4H]4- 
 














































Azido Molecular Weight = 1660.41 Da 








































Amino Molecular Weight = 1634.42 Da 
Amino ESI-MS observed m/z: 407.7 [M-4H]4- 
 














































Azido Molecular Weight = 1664.43 Da 








































Amino Molecular Weight = 1638.43 Da 
Amino ESI-MS observed m/z: 545.1 [M-3H]3- 
 














































Azido Molecular Weight = 1702.45 Da 








































Amino Molecular Weight = 1676.45 Da 
Amino ESI-MS observed m/z: 418.2 [M-4H]4- 
 














































Azido Molecular Weight = 1740.47 Da 








































Amino Molecular Weight = 1714.47 Da 
Amino ESI-MS observed m/z: 342.0 [M-5H]5- 
 




















































Azido Molecular Weight = 1676.42 Da 













































Amino Molecular Weight = 1650.43 Da 
Amino ESI-MS observed m/z: 431.6 [M-4H]4- 
 



















































Azido Molecular Weight = 1836.54 Da 













































Amino Molecular Weight = 1810.54 Da 
Amino ESI-MS observed m/z: 451.8 [M-4H]4- 
 



















































Azido Molecular Weight = 1840.56 Da 













































Amino Molecular Weight = 1814.56 Da 
Amino ESI-MS observed m/z: 452.8 [M-4H]4- 
 



















































Azido Molecular Weight = 1878.58 Da 













































Amino Molecular Weight = 1852.58 Da 
Amino ESI-MS observed m/z: 462.1 [M-4H]4- 
 
Additional information:  
http://www.rsc.org/suppdata/c6/cc/c6cc08204a/c6cc08204a1.pdf (pp 22-24)  
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Azido Molecular Weight = 1878.58 Da 













































Amino Molecular Weight = 1852.58 Da 
Amino ESI-MS observed m/z: 462.2 [M-4H]4- 
 



















































Azido Molecular Weight = 1916.6 Da 













































Amino Molecular Weight = 1890.6 Da 
Amino ESI-MS observed m/z: 377.3 [M-5H]5- 
 























































Azido Molecular Weight = 1997.7 Da 


















































Amino Molecular Weight = 1971.7 Da 
Amino ESI-MS observed m/z: 492.0 [M-4H]4- 
 























































Azido Molecular Weight = 2123.81 Da 


















































Amino Molecular Weight = 2097.81 Da 
Amino ESI-MS observed m/z: 523.4 [M-4H]4- 
 























































Azido Molecular Weight = 2161.83 Da 


















































Amino Molecular Weight = 2135.83 Da 
Amino ESI-MS observed m/z: 426.0 [M-5H]5- 
 























































Azido Molecular Weight = 2199.85 Da 


















































Amino Molecular Weight = 2173.85 Da 
Amino ESI-MS observed m/z: 433.7 [M-5H]5- 
 























































Azido Molecular Weight = 2157.81 Da 


















































Amino Molecular Weight = 2131.87 Da 
Amino ESI-MS observed m/z: 425.4 [M-5H]5- 
 























































Azido Molecular Weight = 2237.87 Da 


















































Amino Molecular Weight = 2211.87 Da 
Amino ESI-MS observed m/z: 441.3 [M-5H]5- 
 




























































Azido Molecular Weight = 2173.82 Da 






















































Amino Molecular Weight = 2147.82 Da 
Amino ESI-MS observed m/z: 428.6 [M-5H]5- 
 





























































Azido Molecular Weight = 2253.88 Da 






















































Amino Molecular Weight = 2227.88 Da 
Amino ESI-MS observed m/z: 444.5 [M-5H]5- 
 





























































Azido Molecular Weight = 2333.93 Da 






















































Amino Molecular Weight = 2307.94 Da 
Amino ESI-MS observed m/z: 460.6 [M-5H]5- 
 





























































Azido Molecular Weight = 2337.95 Da 






















































Amino Molecular Weight = 2311.95 Da 
Amino ESI-MS observed m/z: 461.4 [M-5H]5- 
 




























































Azido Molecular Weight = 2413.99 Da 






















































Amino Molecular Weight = 2387.99 Da 
Amino ESI-MS observed m/z: 476.5 [M-5H]5- 
 














































































Azido Molecular Weight = 3232.66 Da 








































































Amino Molecular Weight = 3206.66 Da 
Amino ESI-MS observed m/z: 533.42 [M-6H]6- 
 














































Azido Molecular Weight = 1542.34 Da 








































Amino Molecular Weight = 1516.34 Da 
Amino ESI-MS observed m/z: 504.5 [M-3H]3- 
 













































Azido Molecular Weight = 1580.36 Da 








































Amino Molecular Weight = 1554.36 Da 
Amino ESI-MS observed m/z: 517.0 [M-3H]3- 
 













































Azido Molecular Weight = 1820.53 Da 








































Amino Molecular Weight = 1794.53 Da 
Amino ESI-MS observed m/z: 447.7 [M-4H]4- 
 



















































Azido Molecular Weight = 1718.46 Da 













































Amino Molecular Weight = 1692.46 Da 
Amino ESI-MS observed m/z: 422.2 [M-4H]4- 
 



















































Azido Molecular Weight = 1756.48 Da 












































Amino Molecular Weight = 1730.48 Da 
Amino ESI-MS observed m/z: 575.7 [M-3H]3- 
 



















































Azido Molecular Weight = 1996.65 Da 












































Amino Molecular Weight = 1970.65 Da 
Amino ESI-MS observed m/z: 491.5 [M-4H]4- 
 



















































Azido Molecular Weight = 1958.63 Da 












































Amino Molecular Weight = 1932.63 Da 
Amino ESI-MS observed m/z: 482.1 [M-4H]4- 
 
Additional information:  


















































Azido Molecular Weight = 1836.54 Da 












































Amino Molecular Weight = 1810.54 Da 
Amino ESI-MS observed m/z: 451.6 [M-4H]4- 
 
Additional information:  


















































Azido Molecular Weight = 2076.71 Da 












































Amino Molecular Weight = 2050.71 Da 
Amino ESI-MS observed m/z: 409.2 [M-5H]5- 
 
Additional information:  





















































Azido Molecular Weight = 1921.66 Da 
















































Amino Molecular Weight = 1895.66 Da 
Amino ESI-MS observed m/z: 631.0 [M-3H]3- 
 






















































Azido Molecular Weight = 1959.68 Da 
















































Amino Molecular Weight = 1933.68 Da 
Amino ESI-MS observed m/z: 643.4 [M-3H]3- 
 






















































Azido Molecular Weight = 1997.7 Da 
















































Amino Molecular Weight = 1971.7 Da 
Amino ESI-MS observed m/z: 491.8 [M-4H]4- 
 






















































Azido Molecular Weight = 2317.92 Da 
















































Amino Molecular Weight = 2291.93 Da 
Amino ESI-MS observed m/z: 457.2 [M-5H]5- 
 




















































Azido Molecular Weight = 2039.73 Da 














































Amino Molecular Weight = 2013.73 Da 
Amino ESI-MS observed m/z: 502.6 [M-4H]4- 
 



















































Azido Molecular Weight = 2077.75 Da 














































Amino Molecular Weight = 2051.75 Da 
Amino ESI-MS observed m/z: 409.3 [M-5H]5- 
 




















































Azido Molecular Weight = 2359.96 Da 














































Amino Molecular Weight = 2333.96 Da 
Amino ESI-MS observed m/z: 465.8 [M-5H]5- 
 




















































Azido Molecular Weight = 2397.98 Da 














































Amino Molecular Weight = 2371.98 Da 
Amino ESI-MS observed m/z: 473.3 [M-5H]5- 
 
























































Azido Molecular Weight = 2097.78 Da 


















































Amino Molecular Weight = 2071.78 Da 
Amino ESI-MS observed m/z: 517.1 [M-4H]4- 
 
























































Azido Molecular Weight = 2135.8 Da 


















































Amino Molecular Weight = 2109.8 Da 
Amino ESI-MS observed m/z: 526.4 [M-4H]4- 
 
























































Azido Molecular Weight = 2173.82 Da 


















































Amino Molecular Weight = 2147.82 Da 
Amino ESI-MS observed m/z: 535.8 [M-4H]4- 
 
























































Azido Molecular Weight = 2494.05 Da 


















































Amino Molecular Weight = 2468.05 Da 
Amino ESI-MS observed m/z: 492.5 [M-5H]5- 
 


























































Azido Molecular Weight = 2215.86 Da 




















































Amino Molecular Weight = 2189.86 Da 
Amino ESI-MS observed m/z: 546.6 [M-4H]4- 
 



























































Azido Molecular Weight = 2253.88 Da 





















































Amino Molecular Weight = 2227.88 Da 
Amino ESI-MS observed m/z: 556.1 [M-4H]4- 
 



























































Azido Molecular Weight = 2574.1 Da 





















































Amino Molecular Weight = 2528.11 Da 
Amino ESI-MS observed m/z: 508.7 [M-5H]5- 
 














































































Azido Molecular Weight = 3072.54 Da 








































































Amino Molecular Weight = 33046.54 Da 
Amino ESI-MS observed m/z: 760.55 [M-4H]4- 
 













































































Azido Molecular Weight = 3514.86 Da 








































































Amino Molecular Weight = 3488.87 Da 
Amino ESI-MS observed m/z: 435.06 [M-8H]8- 
 













































































Azido Molecular Weight = 3552.88 Da 








































































Amino Molecular Weight = 3526.89 Da 
Amino ESI-MS observed m/z: 439.75 [M-8H]8- 
 













































Azido Molecular Weight = 4564.73 Da 







































Amino Molecular Weight = 4538.73 Da 
Amino ESI-MS observed m/z: 503.14 [M-9H]9- 
 













































Azido Molecular Weight = 1862.57 Da 







































Amino Molecular Weight = 1836.57 Da 
Amino ESI-MS observed m/z: 458.2 [M-4H]4- 
 












































Azido Molecular Weight = 1900.59 Da 







































Amino Molecular Weight = 1874.59 Da 
Amino ESI-MS observed m/z: 467.6 [M-4H]4- 
 

















































Azido Molecular Weight = 2076.71 Da 











































Amino Molecular Weight = 2050.71 Da 
Amino ESI-MS observed m/z: 511.5 [M-4H]4- 
 


















































Azido Molecular Weight = 2440.02 Da 













































Amino Molecular Weight = 2414.02 Da 
Amino ESI-MS observed m/z: 481.6 [M-5H]5- 
 













































































Azido Molecular Weight = 3632.94 Da 







































































Amino Molecular Weight = 3606.94 Da 
Amino ESI-MS observed m/z: 449.84 [M-8H]8- 
 










































































Azido Molecular Weight = 3632.94 Da 



































































Amino Molecular Weight = 3606.94 Da 
Amino ESI-MS observed m/z: 449.84 [M-8H]8-      Additional information:  Not available. 
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Azido Molecular Weight = 1462.28 Da 








































Amino Molecular Weight = 1436.28 Da 
Amino ESI-MS observed m/z: 477.9 [M-3H]3- 
 













































Azido Molecular Weight = 1500.3 Da 








































Amino Molecular Weight = 1474.3 Da 
Amino ESI-MS observed m/z: 490.4 [M-3H]3- 
 













































Azido Molecular Weight = 1740.47 Da 








































Amino Molecular Weight = 1714.47 Da 
Amino ESI-MS observed m/z: 342.0 [M-5H]5- 
 



















































Azido Molecular Weight = 1638.4 Da 













































Amino Molecular Weight = 1612.41 Da 
Amino ESI-MS observed m/z: 536.4 [M-3H]3- 
 



















































Azido Molecular Weight = 1676.42 Da 












































Amino Molecular Weight = 1650.43 Da 
Amino ESI-MS observed m/z: 549.1 [M-3H]3- 
 



















































Azido Molecular Weight = 1916.6 Da 












































Amino Molecular Weight = 1890.6 Da 
Amino ESI-MS observed m/z: 377.2 [M-5H]5- 
 






















































Azido Molecular Weight = 1841.6 Da 
















































Amino Molecular Weight = 1815.6 Da 
Amino ESI-MS observed m/z: 604.1 [M-3H]3- 
 






















































Azido Molecular Weight = 1879.62 Da 
















































Amino Molecular Weight = 1853.62 Da 
Amino ESI-MS observed m/z: 462.5 [M-4H]4- 
 






















































Azido Molecular Weight = 1917.64 Da 
















































Amino Molecular Weight = 1891.64 Da 
Amino ESI-MS observed m/z: 471.8 [M-4H]4- 
 






















































Azido Molecular Weight = 2161.83 Da 
















































Amino Molecular Weight = 2135.83 Da 
Amino ESI-MS observed m/z: 426.1 [M-5H]5- 
 
























































Azido Molecular Weight = 2017.72 Da 


















































Amino Molecular Weight = 1991.72 Da 
Amino ESI-MS observed m/z: 496.9 [M-4H]4- 
 
























































Azido Molecular Weight = 2173.82 Da 


















































Amino Molecular Weight = 2067.76 Da 
Amino ESI-MS observed m/z: 515.9 [M-4H]4- 
 
























































Azido Molecular Weight = 2413.99 Da 


















































Amino Molecular Weight = 2387.99 Da 
Amino ESI-MS observed m/z: 397.0 [M-6H]6- 
 

















































Azido Molecular Weight = 2038.69 Da 











































Amino Molecular Weight = 2012.69 Da 
Amino ESI-MS observed m/z: 401.6 [M-5H]5- 
 
Additional information:  





Supplementary Figure 1: Structural analysis of 7-2311-Az.  MS spectrum of azido-tagged 
7-2311.  The measured m/z was 406.8 which represents [M-5H]5-. 
 
Supplementary Figure 2: Structural analysis of 7-2311-NH2.  MS spectrum of amino-





Supplementary Figure 3: 1H NMR of compound 7-2311-Az (850 MHz, D2O).  The 
signals of anomeric protons are indicated.  The anomeric protons resonate at δ 5.59, 5.58, 





Supplementary Figure 4: 13C-NMR of compound 7-2311-Az (600 MHz, D2O).  The 
signals of anomeric carbons are indicated.  The anomeric carbons resonate at δ 104.59, 
104.53, 102.90, 101.74, 101.74, 99.56 and 99.32.  The chemical structure of 7-2311-Az is 





Supplementary Figure 5. 1H-13C HSQC NMR spectrum of compound 7-2311-Az (850 
MHz, D2O). The anomeric signals are indicated. Chemical structure of compound 7-2311-Az 




Supplementary Figure 6. LCMS/MS spectrum of compound 7-2311-Az after treatment 
with heparinase. The products of heparinase treatment are labeled with AMAC and 
represented as Peak I, Peak II and Peak III. The MS analysis of each peak is represented in 





Supplementary Figure 7. MS spectrum of compound 7-2311-Az (Peak I).  Peak 1 elutes 
at 6.23 minutes and represents ΔUA-GlcNS6S + AMAC.  This represents rings E and D, and 





Supplementary Figure 8. MS spectrum of compound 7-2311-Az (Peak 2).  Peak 2 elutes 
at 6.6 minutes and represents the [M-2H]2- ion of the trisaccharide ΔUA2S-GlcNS6S3S-






Supplementary Figure 9. MS spectrum of compound 7-2311-Az (Peak 3).  Peak 3 elutes 
at 8.62 minutes and represents the AMAC labeled disaccharide GlcA-GlcNAc6S.  This 
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